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ABSTRACT
Investigation of the Oxidation/Reduction of PRMT1,
Substrate Interaction with PRMT1, and the
Role of Arginine Methylation in RNA Surveillance

by

Damon V. Nitzel, Master of Science
Utah State University, 2013

Major Professor: Dr. Joan M. Hevel
Department: Chemistry and Biochemistry

Protein arginine methylation is an abundant post-translational modification
catalyzed by protein arginine methyltransferases (PRMTs). Arginine methylation plays
important roles in a variety of cellular pathways and human diseases. PRMT1, the
predominant PRMT, catalyzes approximately 85% of all protein arginine methylation in
vivo. While many details of how PRMT1 functions have been uncovered through the
past two decades, there are many details which remain unclear, including how arginine
methylation is regulated, how PRMT1 binds substrates, and what role PRMTs play in
RNA surveillance. Our recent data presented in this thesis showed that reduction of the
PRMT1 enzyme, following recombinant expression and purification, changes both
enzymatic activity and oligomeric state. A cysteine residue(s) was found to be
responsible for the observed redox chemistry in PRMT1 and at least one parameter in
the kinetic mechanism, S-adenosylmethionine (AdoMet) binding, was faster with a
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reduced enzyme. This work suggests exciting potential for the regulation of PRMTs in
vivo by oxidative stress.
In addition to studying the effects of reduction/oxidation on PRMT1, a foundation
for future experiments was laid. These experiments investigate substrate recognition by
PRMTs and what the role arginine methylation may play in RNA processing and
surveillance. To better understand how PRMTs selectively bind a wide variety of
substrates, I have designed and preliminarily characterized several Hmt1 (the S.
cerevisiae homologue of PRMT1) variants. These variants will be used for crystallization
trials of a homogeneous complex, containing Hmt1, AdoMet, and a peptide substrate,
capable of revealing specific chemical interactions between Hmt1 and the peptide
substrate. To further our understanding of Hmt1’s role in RNA processing and
surveillance, particularly in RNA degradation pathways, I extracted yeast RNA from both
wild type and Hmt1-null cells. The RNA was probed using a S. cerevisiae whole-genome
microarray. This analysis revealed that Hmt1 exhibits statistically significant effects in
several broad areas including molecular function, biological processes, cellular
components, and some KEGG pathways. The presented studies have revealed the
exciting potential for an in vivo regulatory mechanism of PRMT1 and each study is
primed for further investigation both in vivo and in vitro.
(84 pages)
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PUBLIC ABSTRACT
Investigation of the Oxidation/Reduction of PRMT1, Substrate Interaction with PRMT1,
and the Role of Arginine Methylation in RNA Surveillance
Enzymes are the machines of our cells. Just like machines, it takes a lot of
energy to create them, and they then serve only the function they were created for. If we
want to change the function of a machine, we need to modify it. Similarly, enzymes can
be modified after their creation to give them additional function. These modifications can
do a variety of things including activating (on) or inactivating (off) an enzyme, changing
the enzyme’s location in the cell, and targeting the enzyme for destruction. This thesis
focuses on a single class of enzymes, protein arginine methyltransferases (PRMTs),
which are capable making small modifications to other proteins. This modification is
called methylation because the enzyme transfers one or two methyl groups to specific a
specific location(s) on the target protein (substrate).
This small but significant change is involved in cellular processes such as
transcriptional regulation, DNA repair, subcellular localization, and signal transduction.
Due to PRMTs broad involvement in the cell, it is unsurprising that protein methylation is
involved in several types of cancer, cardiovascular disease, and many others. Detailed
study of PRMTs to understand methyl group transfer, substrate targeting, and how they
are controlled by the cell is essential for the development of therapeutic drugs capable of
treating diseases associated with protein arginine methylation. This thesis presents
studies which continue to provide insight into the function of PRMTs by addressing the
effects of oxidative stress on PRMT1, how PRMTs interact with their substrates at the
atomic level, and how PRMTs are involved in the processing of RNAs.
Damon V. Nitzel
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CHAPTER 1
INTRODUCTION
INTRODUCTORY BACKGROUND
Communication is vital for individual entities to function together to achieve
objectives that cannot be achieved alone. Cells in our bodies use inter/intracellular
communication, thereby working in harmony to support life. One method cells use to
communicate is through varied protein function. Protein function can be regulated during
creation through transcriptional regulation, genomic recombination, alternative splicing,
and altered transcriptional termination. Existing protein function can be further expanded
through the use of post-translational modifications (PTMs). Chemical modifications on
proteins can lead to changes in localization, molecular interactions, proteolytic cleavage,
total degradation, enzymatic activity, and protein stability. The primary objective of this
document is to expand our understanding of how protein arginine methylation (one type
of PTM) is regulated.
PTMs and Cellular Signaling
Many PTMs are used to transmit signals both inside and outside of the cells
including

phosphorylation,

methylation,

acetylation,

glycosylation,

ubiquitination,

nitrosylation, and lipidation to name a few. A common example of this is observed by the
body’s response to increased glucose levels in the blood. As insulin levels increase in
the blood and bind to the insulin receptors, the receptor undergoes a conformational
change that induces autophosphorylation, thereby activating the subunit’s kinase
activity1. The activated receptor kinase phosphorylates a newly bound protein, insulin
receptor substrate (IRS-1), a modification which is then recognized by the Src-homology
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2 domain (SH2) of the p85 subunit of Phosphatidylinositol-3-Kinase (PI-3K). This
induced protein-protein (IRS-1 to PI-3K) interaction activates a cascade of new
interactions and alters the activity of many enzymes which stimulates cellular responses
to insulin such as gene expression, glycogen synthesis, and protein synthesis. Just as
phosphorylation is a PTM used to signal cellular responses to increased insulin levels,
many different biological signaling pathways, to be discussed later, use the posttranslational modification methylation in signal transduction.
The Methyl Group Donor S-adenosyl-L-methionine
In order to better understand the significance of protein methylation, it is
important to first gain a basic understanding of how biological methylation is performed.
Biological methyltransferases (MTases), the class of enzymes which catalyze methyl
transfer, predominantly use S-adenosyl-L-methionine (AdoMet or SAM, Figure 1-1) as a
methyl donor. AdoMet is second only to adenosine triphosphate (ATP) in use as an
enzyme substrate and is used in metabolic pathways including transmethylation,
transsulfuration, and aminopropylation2. AdoMet’s favorable energetics (a low ΔG = -17
kcal/mol) from the charged methylsulfonium center are what make it preferable over
other methyl donors such as N5-methyltetrahydrofolate3. The AdoMet methyl group (CH3) is transferred by the methyltransferases and a methylated product and Sadenosyl-L-homocysteine (AdoHcy or SAH, Figure 1-1) is generated. Methyltransferase
substrates are vast and include macro molecules such as Proteins, DNA, RNA4,5, and
small molecules such as arsenite6,7 and sterols8,9. Methyltransferases are generally
thought to use an SN2-like mechanism (Figure 1-1), transferring the methyl group onto
the target substrate via an inversion of symmetry10,11.
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Figure 1-1: Diagram of protein arginine methylation by PRMT1.

Protein Methylation
One form of biological methylation, protein methylation, is involved in diverse
cellular processes such as transcriptional regulation12, DNA repair13, subcellular
localization of proteins14, signal transduction and nuclear transport15. Protein
methyltransferases (PMTs) predominantly methylate nitrogen (N-methylation) and
oxygen (O-methylation) atoms of amino acid side chains. Methylation also occurs on
carbon (C-methylation) and sulfur (S-methylation) atoms. The most prevalent type of
methyl transfer occurs on nitrogen atoms on the side chains of lysine, arginine, histidine,
glutamine, and asparagine16. Lysine methylation can occur as mono-, di-, or trimethylation on the ε-amino group of its side chain. Arginine methylation occurs as either
mono- (MMA), asymmetrical di-methylation (ADMA), or symmetrical di-methylation
(SDMA)17,18. The Protein Arginine Methyltransferase (PRMT) family in mammals consists
of nine enzymes which can be classified by type of methylation as follows: type I PRMTs
(PRMT1, 2, 3, 4, 6 and 8)catalyze the formation of MMA and ADMA, type II PRMTs
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(PRMT5, 9) form MMA and SDMA, and type III PRMTs (PRMT7) are limited to formation
of MMA19–21. The majority of work presented in this document is performed with PRMT1
(or

its

S.

cerevisiae

homologue,

heterogeneous

nuclear

ribonucleoprotein

methyltransferase [Hmt1]), the predominant PRMT responsible for biological arginine
methylation.
SIGNIFICANCE
Biological Significance
The arginine methylation field has rapidly expanded as awareness of the
modification’s involvement in a vast array of cellular processes and its significance in
organism viability has increased. The majority of protein methylation is involved in
cellular processes such as transcriptional regulation, pre-mRNA splicing and mRNA
transport, DNA damage repair, and signal transduction.
Arginine methylation is essential for developing life— PRMT1 was shown to be
an essential protein in a study where PRMT1 null mice died in early embryonic
development22,23. PRMT2, -3 and -4 knockouts were embyronically viable but caused the
following varied effects respectively; abnormal fibroblast activity and increased
resistance to apoptosis24, smaller body mass25, and smaller body mass followed by
death shortly after birth26. These studies emphasize the importance of understanding
how methylation is catalyzed, used as a signal, and regulated.
Transcriptional regulation— Protein methylation on transcriptional factors, such
as NF-κB27, PPARxγ28, RUNX129, p5330, p30031, YY132 and histone proteins, mainly H3
and H4, is responsible for both upregulation and repression of gene transcription.
Generally, PRMT1 and PRMT4 are reported as transcriptional coactivators19. PRMT 1
methylation of the transcription factor RUNX1 promotes dissociation of the transcription
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repressor SIN3A, resulting in RUNX1 transcriptional activity29. Increased lysine
acetylation caused by asymmetric dimethylation H4R3 by PRMT1 leads to transcriptional
activation33–35. Alternatively, H4R3 can be symmetrically dimethylated by PRMT5 which
recruits DNA methyltransferase DNMT3A resulting in transcriptional silencing36. These
results and many others show the important role(s) of protein methylation in controlling
gene expression and in response to cellular and environmental stimuli.
DNA damage repair— Maintaining correct DNA sequences and repairing
damaged DNA is of high priority in cells. DNA damaged by double strand breaks (DSBs)
is addressed by the MRN complex (MRE11/Rad50/NBS1). Meiotic recombination 11
(MRE11) is methylated both in vitro and in vivo by PRMT137. The methylation of
MRE11’s GAR motif is required for exonuclease activity and intra-S phase DNA damage
response via interaction with nuclear structures38. The tumor suppressor protein p53 is
another important player in DNA repair, binding damaged DNA and activating genes
which promote cell cycle arrest39. PRMT5 has been shown to regulate p53’s target gene
specificity and PRMT5 depletion results in p53 dependent apoptosis30. Interestingly,
PRMT6 is directly involved in regulating p53 gene expression levels. PRMT6 is recruited
to the Trip53 promoter region where it asymmetrically dimethylates H3R2 which acts as a
signal for H3K4 trimethylation, which in turn signals gene repression40.
Signal transduction— Reversible PTMs are the most prominent modifications
used in cellular signaling; however many examples of what is thought to be irreversible
protein arginine methylation show it as a significant signaling contributor. PRMT6
regulates p53 gene expression levels40, described above, as well as regulating cell cycle
progression by repressing cyclin-dependent kinase (CDK) inhibitors41. PRMT1
interaction with the interferon α/β (IFN α/β) receptor was shown in 198442. Subsequently,
IFN α/β-induced transcription was shown to require arginine methylation of STAT-1.

6
STAT-1 arginine methylation is required because in an un-methylated state, STAT-1
exhibits impaired DNA binding due to the association of PIAS1, a STAT inhibitor, and
with

phosphorylated

STAT-1

dimers43.

In

yeast

cells,

Hmt1

promotes

the

nucleocytoplasmic transport of mRNA-binding proteins Yra1 and Hrp1 through
methylation44. In addition, loss of Hmt1 methylation affects the kinetics of HSP104
mRNA production, observed in vivo by comparing wild type and Hmt1-/- strains under
heat stress while monitoring a fluorescent signal generated by pooling mRNA in the
nucleus44. Hmt1’s influence in heat shock protein mRNA production indicates that Hmt1
methylation plays an important signaling role in the cellular response to heat shock.
Hmt1’s role in RNA surveillance and processing is becoming increasingly
apparent. Hmt1 methylates the RNA-binding protein Npl3 during the metabolism of
nuclear pre-mRNA45. Hmt1 methylation is inhibited by Air1/2, a component of the
TRAMP complex, which interacts with a wide range of substrates including tRNAs,
snoRNAs, snRNAs, ncRNAs, rRNAs, some mRNAs, and cryptic unstable transcripts 46.
The association of Air1 or Air2 with Hmt1 introduces the concept of a role of arginine
methylation in RNA processing on non-coding RNAs (ncRNA). To further understand
Hmt1’s role in global RNA surveillance and processing, as discussed in Chapter 4, a
microarray experiment was performed as an exploratory technique to monitor global
RNA levels. This experiment was based off two previous studies, one which compared
the mRNA levels in wild type (Hmt1) and Hmt1-null (Hmt1-/-) S. cerevisiae (yeast)
cells44, and another which analyzed levels of RNA present after RNA was allowed to
degrade for 45 minutes in wild type and Lrp1-null (an unrelated protein) yeast cells47. In
preparation for the microarray analysis, these two techniques were combined to prepare
RNA that would allow comparison of total RNA level differences (not just mRNAs) in wild
type (Hmt1) and Hmt1-null (Hmt1-/-) cells, specifically differences relating to the
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degradation of RNAs. Genes indentified in this comparison can then be further
investigated for interactions with Hmt1 and how they are processed because of these
interactions.
PRMT1 and Human Disease
Many disease states are associated with protein arginine methylation, which is
unsurprising given arginine methylation’s involvement in so many cellular processes, a
few of which have been discussed. The importance of proper regulation is evident in
studies linking PRMT’s to cancer, cardiovascular disease, viral pathogenesis, spinal
muscular atrophy, and multiple sclerosis. To impart a sense of medical relevance to my
studies on PRMT1, I will briefly discuss the role arginine methylation is cancer and
cardiovascular disease.
Arginine methylation and cancer—As previously mentioned PRMT1 and PRMT4
(CARM1) act as general transcriptional coactivators and disregulation is likely to affect
levels of a variety of transcriptional pathways. Increased PRMT1 mRNA levels in breast
cancer cell lines were reported in 200748. Additionally, studies in mouse primary
hematopoietic cells showed a chain of protein interactions controlling self renewal
properties partly due to implicated methylation of Sam68, a well characterized PRMT1
substrate49. Increased expression of PRMT4 is observed in castration-resistant prostate
cancer and in aggressive breast tumor cells that also express high levels of the
oncogenic coactivator AIB1, and AIB1’s activity and stability is regulated through
methylation by PRMT450,51. PRMT4 presence is required for estrogen-induced
proliferation of the MCF-7 breast cancer cell line, likely through association with AIB1
which is required for recruitment of PRMT4 to ERα-regulated promoter regions52. In
prostate cancer cells, PRMT4 knockdown by siRNA inhibited cell proliferation through
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induced apoptosis, therefore requiring PRMT4 function to maintain viability53. Gastric
cancer, lymphoma and leukemia cells show increased levels of PRMT554,55. PRMT5
interacts with, through the linking molecule AJUBA,

and inhibits the activity of the

transcription factor SNAIL, a repressor of the oncoprotein E-cadherin, ultimately resulting
in enhanced cellular proliferation56.
Arginine methylation and cardiovascular disease—The free methylarginine
species ADMA and MMA, but not SDMA, inhibit nitric oxide synthase (NOS), an enzyme
which generates nitric oxide (NO) which is involved in the cardiovascular, immune, and
neurological systems14. Free methylarginines are produced by proteolysis of methylated
proteins and metabolized by dimethylarginine dimethylaminohydrolase (DDAH), creating
a careful balance of ADMA blood levels. A study, in which DDAH1 knockout mice
accumulated ADMA and exhibited reduced NO signaling, resulted in impaired vascular
homeostasis. This indicates that a disruption of the ADMA blood level balance may
increase risk of cardiovascular disease57. In addition, ADMA levels were elevated in
cases of atherosclerosis, hypercholesterolemia, and hypertension. Clearly cells need to
tightly regulate ADMA blood levels, and do this in part using the DDAH enzyme. While
no studies directly link PRMT regulation to decreased ADMA levels, inhibition of PRMTs
may be used as an alternative method of ADMA level control, which is one direction the
medical community could take to regulate ADMA pharmacologically. A cardiology study
exemplifies this by using the PRMT inhibitor AMI-1 to decrease PRMT1 activity and
thereby decrease ADMA levels58. Unfortunately, overarching PRMT1 inhibition could be
detrimental to health because of the scope of arginine methylation throughout the body,
creating a need for substrate specific and methylation state specific inhibitors.
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IN-DEPTH BACKGROUND
Protein Arginine Methyltransferases
It should be clear that PRMTs are extremely important enzymes involved in many
human diseases and biological processes. In order to develop treatments for diseases
caused by irregular arginine methylation, we need to continue to expand our
understanding of the PRMT enzymes. The following sections provide important
background knowledge on the PRMT1 protein structure, the variety of PRMT1
substrates, and how arginine methylation is regulated.
Previous studies show that PRMT1 accounts for approximately 85% of the total
protein arginine methylation in vivo and is thus a primary subject of study in the field59.
PRMT1 is known to localize to both the nucleus and the cytoplasm and has a wide
variety of substrates, a large portion of which are methylated in glycine-arginine rich
domains60,61.
Structural Insight into PRMT1
In order to gain insight into the molecular mechanisms of PRMTs, several crystal
structures have been solved to date; rat PRMT162, yeast RMT1/Hmt163, rat PRMT364,
mouse PRMT465, PRMT 5 from Caenorhabditis elegans66, and plant-specific PRMT10
from Arabidoplis thaliana67. The PRMT structures all exist as homodimers (except
hexameric Hmt1) with each monomer containing three common elements: an AdoMet
binding domain partially conserved in other AdoMet-dependent MTases4,11,64,68, a βbarrel unique to the PRMTs62,64, and a dimerization arm which varies in length (Figure
2).
The structure of rat PRMT1 (Figure 1-2) is of particular note because the
crystallized complex contains a 19 amino acid peptide substrate derived from fibrillarin
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Figure 2: The crystal structure of rat PRMT1 (PDB:1OR8). Highlighted in the
structure is SAH (yellow sticks) and arginine (green sticks) in the binding pocket, the
modeled R3 peptide backbone (green spheres), the dimerization arm (orange), and the
unique β-barrel (pale yellow).

(R3, GGRGGFGGRGGFGGRGGFG) and the reaction product AdoHcy. This structure
introduced a picture of the PRMT active site, leading to mutagenic analysis of residues
interacting with the substrate arginine. The first of these studies by Zhang et al. involves
two active site glutamates (E144 and E153), coined the “double-E” loop, which stabilize
the substrate arginine’s guanidine nitrogen via hydrogen bonding62. The importance of
these glutamates is indicated by their structural conservation in the active sites of all
solved structures; PRMT1 (E144 and E153), PRMT3 (E326 and E335), CARM1 (E258
and E267) PRMT5 (E499 and E508), and plant specific PRMT10 (E143 and E152). Sitedirected mutagenesis of theseconserved glutamate residuesshowed that proper
positioning of the negative charge is essential for catalysis62.
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A second study in the Hevel lab lead by Dr. Shanying Gui, as well as other
groups, investigated a pair of methionine residues (M48 and M155) in the crystal
structure of PRMT1 that reside close to the guanidine group of the substrate
arginine66,69. These methionines are positioned such that they are able to regulate the
formation of MMA and ADMA in PRMT1 (a type I PRMT) by properly orienting the
substrate arginine. The M48 equivalent residue in PRMT5 (a type II PRMT) is a
phenylalanine. Interestingly, a M48F PRMT1 variant gained the ability to produce SDMA.
These studies show how invaluable structural data is for improved experimental design
and further understanding of enzyme characteristics. The structures of PRMT1 and
Hmt1 were essential for my investigations of how oxidation/reduction effects PRMT1
(chapter 2) and how substrates interact with PRMT1 (chapter 3).
Methylation of PRMT Substrates
Understanding specific molecular interactions between PRMTs and substrates is
important for therapeutical drug design. Identifying these interactions is difficult because
PRMTs have numerous substrates, many of which contain multiple arginines which are
selectively methylated. Most PRMTs exhibit a substrate preference in glycine and
arginine rich (GAR) motifs in either “RGG” or “RXR” sequences. However, substrate
profiling studies of PRMT1 revealed additional amino acid sequences that expand
beyond the typical “RGG” model sequence, indicating a wider capability of substrate
selection by PRMTs70,71.
The complexity of arginine methylation is demonstrated by histone proteins,
which are common substrates for all PRMTs, with methylation observed on histone 3
(H3) by PRMT412,72, -573,74, and -675 and on histone 4 (H4) by Hmt176,77, PRMT112,33, -278,
-379, -580, -675,-774, -921, and -1067. Transcriptional regulation is controlled by PTMs on
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histone tails and PRMTs demonstrate site preferences for methylation of various
arginines on the histone proteins.

For example, PRMT4 prefers the R17 and R26

residues of H3 as methylation targets. In vivo, PRMT1 and PRMT5 both target the R3
residue of H4, introducing ADMA and SDMA respectively. Incredibly, the subtle
difference(s) between the ADMA and SDMA methylation states lead to opposite
transcriptional consequences33–36,81. Adding to the complexity, MMA that was previously
thought to be an intermediate of an ADMA or SDMA end product was shown as an
active in vivo methylation state at the R2 reside of H3. Incredibly, the ADMA modification
was shown to have a distinctly different transcriptional output from this newly observed
MMA methylation state82. It is clear that arginine methylation is extremely complex.
Unfortunately little is known about the molecular interactions between PRMTs and their
substrates.
Molecular Interactions between PRMTs and Substrates
Structural information typically lends the most clarity to detailed interactions
between enzymes and their substrate(s) at the atomic level. As previously described, the
R3 peptide was co-crystallized with the rat PRMT1 enzyme. Unfortunately, data required
for precise modeling of the R3 peptide was incomplete, likely due to an ability of PRMT1
to bind the R3 peptide in multiple orientations. This structure of rat PRMT1 with the R3
substrate bound aligned to the structure of the yeast homologue Hmt1 serves as the
starting point for enzyme:substrate interaction studies to be discussed in chapter 3. Our
working hypothesis is that we can restrict the binding mode(s) of the R3 peptide
substrate to gain further understanding of molecular interactions involved in substrate
specificity. The broad scope of PRMT’s influences in biological processes indicate a
great need for inhibitors designed with specificity for a targeted disease state, capable of
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leaving other processes unhindered. The unveiling of molecular interactions between
PRMTs and substrates, as well as mechanistic details, aims to lay a foundation for
isoenzyme specific and/or substrate specific inhibition of PRMTs.
Regulation of PRMTs
As with all PTMs, the need to maintain control of signaling is essential. Protein
methylation is no exception and is carefully regulated by protein interactions, active site
residues, product inhibition, post-translational modifications, substrate modifications,
modification removal, and potentially through oxidation/reduction.
Regulation by active site residues— Active site residues inherently play a large
role in overcoming barriers to catalysis. Varying residues in isoenzyme active sites of
lysine and arginine methyltransferases have been implicated in determining product
specificity and therefore the biological outputs associated with varied methylation
states83–87. For example, in the active site of lysine methyltransferases (PKMTs) SET7/9
and SET8, which only produce monomethyl lysine (MMK), replacement of a conserved
tyrosine residue with a phenylalanine results in an active site with enough space to
create di- or trimethyl lysine (DMK or TMK)84,87–90. Previously discussed evidence
showed that two active site methionines of were at least partially responsible for the
output of only ADMA by PRMT1 and only SDMA by PRMT566,69. Both PRMT and PKMT
examples evidence the important role active site residues play in both positioning the
nucleophilic nitrogen in the correct location as well as sterically regulating dimensions of
the active site and thus the methylation state of the product.
Regulation by protein-protein interactions— Protein arginine methylation can also
be regulated via protein-protein interactions, resulting in activation, inhibition, or
modulation of substrate specificity. One clear example of activation through protein-
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protein interactions is provided by PRMT4, which preferentially methylates free histones
36-fold higher than nucleosomes. However, when PRMT4 was associated with the
nucleosomal methylation activator complex (NUMAC), the selectivity of PRMT4 altered
to preferentially methylate nucleosomal histones 6-fold greater than free histones, a 200fold net reversal in specificity91. An example of substrate specificity regulation is provided
by Cooperator of PRMT5 (CORP5). CORP5 is required to coordinate PRMT5 with
reconstituted nucleosomes in vitro and results in inhibition ofH3R8 methylation, but not
methylation of H4R3 or myelin basic protein (MBP), even though all three are known
PRMT5 substrates92. In vivo, cellular depletion of CORP5 causes loss of PRMT5
recruitment to the target gene cyclin E1 (CCNE1) on chromatin, correlating to a loss of
dimethylation at H4R392. These studies show that in vivo, PRMT-related biological
processes can be tuned by regulation of arginine methylation using protein-protein
interactions.
Regulation by PTMs— Post-translational modifications often act as molecular
switches controlling substrate actions. PRMTs can undergo PTMs which alter activity
and substrate specificity. One example of enzyme modification is observed in PRMT4
when Ser217 is phosphorylated. This phosphorylation disrupts Ser217’s hydrogen bond
with neighboring Tyr154, which is required for AdoMet binding, and consequently
enzyme activity is squelched93. Recent unpublished studies in the Hevel Lab are
suggestive of an oxidative modification capable of regulating catalytic activity (chapter
2). Several published studies have weakly linked increased PRMT-1 expression to
oxidative stress94–96; however occurrence of a regulatory post-translational oxidative
modification on PRMTs has not been shown to date. Nevertheless, oxidation as a
regulatory PTM is not a novel concept and is an emerging field seemingly centered on
protein tyrosine phosphatases (PTP)97. The widespread incorporation of cysteine
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residues in many proteins and examples of oxidation/reduction regulating enzymatic
activity in other fields lend credibility to the idea of oxidative/reductive regulation playing
a role in the PRMT field. This concept is investigated in Chapter 2 of this thesis.
Regulation through substrate modification— In addition to enzyme modification, a
model for substrate modifications that alter PRMT specificity is provided by histones.
Histone tails can contain many PTMs, including varied methylation, phosphorylation,
acetylation, and ubiquitination which make up what is commonly referred to as the
histone code. Generally the histone code is thought to control chromatin structure
through protein recruitment; additionally modifications that make up the code can
regulate further modification. This is evidenced when H3K9 is acetylated and methylation
of H3R8 by PRMT5 is inhibited73. Also, the occurrence of H3K4 tri-methylation by an MLL
complex precludes the occurrence of H3R2 dimethylation by PRMT6 and vice
versa72,98,99.
Regulation by reversing methylation— Post-translational modifications are
commonly regulated using cellular counter measures. Acetylation and phosphorylation
are PTMs that are dynamically regulated, serving as on-off switches in many widely
known pathways, and are unlike methylation signals which are seemingly difficult to
reverse. The most rapid method of reversing a signal is to remove the PTM that caused
it. However, methylation was widely considered irreversible until a histone demethylase
was characterized in 2004100. Methylation of H3K4 has been shown to be removable by
histone-Lys-specific demethylase (LSD1), requiring the FAD cofactor and generating
hydrogen peroxide (H2O2) and formaldehyde (CHO) as byproducts. Arginine methylation
is currently thought to be irreversible, although one study in 2007 identified a Jumonji
domain-containing 6 protein (JMJD6) which reportedly demethylated H3R2 and H4R3101.
Unfortunately, this observation has proven irreproducible in other labs prominent in the
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methylation field. The crystal structure of JMJD6 was solved in 2010 and structural data,
supported by mutational studies, suggests thatthe enzyme catalyzes C-5 hydroxylation
as opposed to N-demethylation102. The combination of lack of reproducibility and
discovery of an alternative function invokes uncertainty in the existence of an arginine
demethylase. Consequently, proteolysis of the methylated protein is speculated as the
predominant method of signal quenching103.
Regulation via synthetic small molecule inhibitors— From a medicinal standpoint,
three mechanisms of pharmacological inhibition that could be used to modulate PRMT1
activity include; imitating AdoMet, imitating a protein substrate with a peptide mimic, or
allosterically interfering with substrate binding. Because AdoMet is a widely used
biological cofactor creating AdoMet analogues, while valuable in vitro, does not have in
vivo significance as this type of inhibitor may not be solely specific to arginine
methylation. Creating peptide mimics allows for inhibitor design that potentially
overcomes

the

barrier

of

enzyme

specificity,

but

introduces

the

common

pharmacological hurdle of efficient and effective drug delivery. Several inhibitors are
known which use both these mechanisms and have arginine methyltransferase
specificity, yet identification of a single PRMT isoform inhibitor continues to be a
challenge71,104,105. A novel approach to this important problem is to use in silico modeling
to identify small molecule inhibitors with PRMT isoform, substrate, and methylation state
specificity. In order for this approach to be taken, a knowledge gap must be closed by
identifying residues responsible for chemical interactions at the PRMT:substrate
interface(s), an important goal addressed in chapter 3.
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CONCLUSION
It is evident that arginine methylation by PRMTs is a significant PTM that has
roles in many essential biological processes. Regulation of such a small but powerful
modification is critical and several of many methods of control have been reviewed here.
Identification and understanding of a problem(s) is the first stage and key to discovering
a solution(s) that correct the problem(s). Similarly, determining the cause of a disease
and how, in these cases, a causal enzyme(s) functions, sets the stage for researching a
method to abate or even cure the selected health defect. In order to contribute to this
field of investigating the biological importance of PRMTs, I have investigated the
oxidation/reduction of rat PRMT1 (Chapter 2), created a variant Hmt1 library to identify
enzyme:substrate interactions (Chapter 3), and screened for differences in residual RNA
levels between wild type and Hmt1-/- yeast cells (Chapter 4). If successful, the shortterm goals of the research at the enzyme characterization stage described in this thesis
will provide a framework for development of small molecules capable of controlling
specific interactions of arginine methylation in biological processes important in healthy
cells.
REFERENCES
1. Lizcano, J. M. & Alessi, D. R. The Insulin Signalling Pathway. Curr. Biol. 12, R236–
R238 (2002).
2. Cantoni, G. L. Biological Methylation: Selected Aspects. Annu. Rev. Biochem. 44,
435–451 (1975).
3. Fujii, K. & Huennekens, F. M. Methionine Synthetase: Characterization of Protein
Components and Mechanisms for Activation and Catalysis. Biochem. Asp. Nutr.
173–183 (Japan Scientific Societies Press, 1979).
4. Cheng, X. & Roberts, R. J. AdoMet-dependent Methylation, DNA
Methyltransferases and Base Flipping. Nucleic Acids Res. 29, 3784–3795 (2001).

18
5. Schubert, H. L., Blumenthal, R. M. & Cheng, X. Many Paths to Methyltransfer: a
Chronicle of Convergence. Trends Biochem. Sci. 28, 329–335 (2003).
6. Aposhian, H. V. Enzymatic Methylation of Arsenic Species and Other New
Approaches to Arsenic Toxicity. Annu. Rev. Pharmacol. Toxicol. 37, 397–419
(1997).
7. Thompson, D. J. A Chemical Hypothesis for Arsenic Methylation in Mammals.
Chem. Biol. Interact. 88, 89–14 (1993).
8. Parker Stephen R. & Nes W. David. Regulation of Sterol Biosynthesis and Its
Phylogenetic Implications. Regul. Isopentenoid Metab. 497, 110–145 (American
Chemical Society, 1992).
9. Goad, L. J. & Goodwin, T. W. The Biosynthesis of Sterols in Higher Plants. Biochem.
J. 99, 735–746 (1966).
10. Chen, S. L., Loffler, K. A., Chen, D., Stallcup, M. R. & Muscat, G. E. O. The
Coactivator-associated Arginine Methyltransferase Is Necessary for Muscle
Differentiation CARM1 Coactivates Myocete Enhancer Factor-2. J. Biol. Chem. 277,
4324–4333 (2002).
11. Koh, S. S. et al. Synergistic Coactivator Function by Coactivator-associated Arginine
Methyltransferase (CARM) 1 and β-Catenin with Two Different Classes of DNAbinding Transcriptional Activators. J. Biol. Chem. 277, 26031–26035 (2002).
12. Chen, D. et al. Regulation of Transcription by a Protein Methyltransferase. Science
284, 2174–2177 (1999).
13. Bedford, M. T. & Richard, S. Arginine Methylation: An Emerging Regulatorof Protein
Function. Mol. Cell 18, 263–272 (2005).
14. Smith, W. A., Schurter, B. T., Wong-Staal, F. & David, M. Arginine Methylation of
RNA Helicase A Determines Its Subcellular Localization. J. Biol. Chem. 279, 22795–
22798 (2004).
15. Gary, J. D. & Clarke, S. RNA and Protein Interactions Modulated by Protein Arginine
Methylation. Prog. Nucleic Acid Res. Mol. Biol. Volume 61, 65–131 (Academic
Press, 1998).
16. Beck-Sickinger, A. G. & Mörl, K. Posttranslational Modification of Proteins.
Expanding Nature’s Inventory. By Christopher T. Walsh. Angew. Chem. Int. Ed. 45,
1020–1020 (2006).
17. Kakimoto, Y. Methylation of Arginine and Lysine Residues of Cerebral Proteins.
Biochim. Biophys. Acta BBA - Protein Struct. 243, 31–37 (1971).
18. Kakimoto, Y. & Akazawa, S. Isolation and Identification of Ng,Ng- and Ng,N’gDimethylarginine, Nε-Mono-, Di-, and Trimethyllysine, and Glucosylgalactosyl- and

19
Galactosyl-δ-hydroxylysine from Human Urine. J. Biol. Chem. 245, 5751–5758
(1970).
19. Bedford, M. T. & Clarke, S. G. Protein Arginine Methylation in Mammals: Who, What,
and Why. Mol. Cell 33, 1–13 (2009).
20. Bedford, M. T. Arginine Methylation at a Glance. J. Cell Sci. 120, 4243–4246 (2007).
21. Cook, J. R. et al. FBXO11/PRMT9, a New Protein Arginine Methyltransferase,
Symmetrically Dimethylates Arginine Residues. Biochem. Biophys. Res. Commun.
342, 472–481 (2006).
22. Pawlak, M. R., Scherer, C. A., Chen, J., Roshon, M. J. & Ruley, H. E. Arginine NMethyltransferase 1 Is Required for Early Postimplantation Mouse Development, but
Cells Deficient in the Enzyme Are Viable. Mol. Cell. Biol. 20, 4859–4869 (2000).
23. Yu, Z., Chen, T., Hebert, J., Li, E. & Richard, S. A Mouse PRMT1 Null Allele Defines
an Essential Role for Arginine Methylation in Genome Maintenance and Cell
Proliferation. Mol. Cell. Biol. 29, 2982–2996 (2009).
24. Yoshimoto, T. et al. The Arginine Methyltransferase PRMT2 Binds RB and
Regulates E2F Function. Exp. Cell Res. 312, 2040–2053 (2006).
25. Swiercz, R., Cheng, D., Kim, D. & Bedford, M. T. Ribosomal Protein rpS2 Is
Hypomethylated in PRMT3-deficient Mice. J. Biol. Chem. 282, 16917–16923 (2007).
26. Yadav, N. et al. Specific Protein Methylation Defects and Gene Expression
Perturbations in Coactivator-associated Arginine Methyltransferase 1-Deficient
Mice. Proc. Natl. Acad. Sci. U. S. A. 100, 6464–6468 (2003).
27. Yang, X.-D., Tajkhorshid, E. & Chen, L.-F. Functional Interplay between Acetylation
and Methylation of the RelA Subunit of NF-κB. Mol. Cell. Biol. 30, 2170–2180 (2010).
28. Yadav, N. et al. CARM1 Promotes Adipocyte Differentiation by Doactivating PPARγ.
EMBO Rep. 9, 193–198 (2008).
29. Zhao, X. et al. Methylation of RUNX1 by PRMT1 Abrogates SIN3A Binding and
Potentiates its Transcriptional Activity. Genes Dev. 22, 640–653 (2008).
30. Jansson, M. et al. Arginine Methylation Regulates the p53 Response. Nat. Cell Biol.
10, 1431–1439 (2008).
31. Lee, Y.-H., Coonrod, S. A., Kraus, W. L., Jelinek, M. A. & Stallcup, M. R. Regulation
of Coactivator Complex Assembly and Function by Protein Arginine Methylation and
Demethylimination. Proc. Natl. Acad. Sci. U. S. A. 102, 3611–3616 (2005).
32. Rezai-Zadeh, N. et al. Targeted Recruitment of a Histone H4-specific
Methyltransferase by the Transcription Factor YY1. Genes Dev. 17, 1019–1029
(2003).

20
33. Strahl, B. D. et al. Methylation of Histone H4 at Arginine 3 Occurs In Vivo and Is
Mediated by the Nuclear Receptor Coactivator PRMT1. Curr. Biol. 11, 996–1000
(2001).
34. Huang, S., Litt, M. & Felsenfeld, G. Methylation of Histone H4 by Arginine
Methyltransferase PRMT1 Is Essential In Vivo for Many Subsequent Histone
Modifications. Genes Dev. 19, 1885–1893 (2005).
35. Wang, H. et al. Methylation of Histone H4 at Arginine 3 Facilitating Transcriptional
Activation by Nuclear Hormone Receptor. Science 293, 853–857 (2001).
36. Zhao, Q. et al. PRMT5-mediated Methylation of Histone H4R3 Recruits DNMT3A,
Coupling Histone and DNA Methylation in Gene Silencing. Nat. Struct. Mol. Biol. 16,
304–311 (2009).
37. Boisvert, F.-M., Dery, U., Masson, J.-Y. & Richard, S. Arginine Methylation of
MRE11 by PRMT1 Is Required for DNA Damage Checkpoint Control. Genes Dev.
19, 671–676 (2005).
38. Boisvert, F.-M., Hendzel, M. J., Masson, J.-Y. & Richard, S. Methylation of MRE11
Regulates its Nuclear Compartmentalization. Cell Cycle Georget. Tex 4, 981–989
(2005).
39. Vousden, K. H. & Lu, X. Live or Let Die: The Cell’s Response to p53. Nat. Rev.
Cancer 2, 594–604 (2002).
40. Neault, M., Mallette, F. A., Vogel, G., Michaud-Levesque, J. & Richard, S. Ablation of
PRMT6 Reveals a Role as a Negative Transcriptional Regulator of the p53 Tumor
Suppressor. Nucleic Acids Res. 40, 9513–9521 (2012).
41. Kleinschmidt, M. A., de Graaf, P., van Teeffelen, H. A. A. M. & Timmers, H. T. M.
Cell Cycle Regulation by the PRMT6 Arginine Methyltransferase through Repression
of Cyclin-Dependent Kinase Inhibitors. PLoS ONE 7, e41446 (2012).
42. Abramovich, C., Yakobson, B., Chebath, J. & Revel, M. A Protein-arginine
Methyltransferase Binds to the Intracytoplasmic Domain of the IFNAR1 Chain in the
Type I Interferon Receptor. EMBO J. 16, 260–266 (1997).
43. Mowen, K. A. et al. Arginine Methylation of STAT1 Modulates IFNα/β-Induced
Transcription. Cell 104, 731–741 (2001).
44. Yu, M. C. et al. Arginine Methyltransferase Affects Interactions and Recruitment of
mRNA Processing and Export Factors. Genes Dev. 18, 2024–2035 (2004).
45. Henry, M. F. & Silver, P. A. A Novel Methyltransferase (Hmt1p) Modifies Poly(A)+RNA-binding Proteins. Mol. Cell. Biol. 16, 3668–3678 (1996).
46. Jackson, R. N. et al. The Crystal Structure of Mtr4 Reveals a Novel Arch Domain
Required for rRNA Processing. EMBO J. 29, 2205–2216 (2010).

21
47. Hieronymus, H., Yu, M. C. & Silver, P. A. Genome-wide mRNA Surveillance is
Coupled to mRNA Export. Genes Dev. 18, 2652–2662 (2004).
48. Goulet, I., Gauvin, G., Boisvenue, S. & Côté, J. Alternative Splicing Yields Protein
Arginine Methyltransferase 1 Isoforms with Distinct Activity, Substrate Specificity,
and Subcellular Localization. J. Biol. Chem. 282, 33009–33021 (2007).
49. Cheung, N., Chan, L. C., Thompson, A., Cleary, M. L. & So, C. W. E. Protein
Arginine-methyltransferase-Dependent Oncogenesis. Nat. Cell Biol. 9, 1208–1215
(2007).
50. Feng, Q., Yi, P., Wong, J. & O’Malley, B. W. Signaling within a Coactivator Complex:
Methylation of SRC-3/AIB1 Is a Molecular Switch for Complex Disassembly. Mol.
Cell. Biol. 26, 7846–7857 (2006).
51. Naeem, H. et al. The Activity and Stability of the Transcriptional Coactivator
p/CIP/SRC-3 Are Regulated by CARM1-Dependent Methylation. Mol. Cell. Biol. 27,
120–134 (2007).
52. Frietze, S., Lupien, M., Silver, P. A. & Brown, M. CARM1 Regulates EstrogenStimulated Breast Cancer Growth through Up-regulation of E2F1. Cancer Res. 68,
301–306 (2008).
53. Majumder, S., Liu, Y., Ford, O. H., Mohler, J. L. & Whang, Y. E. Involvement of
Arginine Methyltransferase CARM1 in Androgen Receptor Function and Prostate
Cancer Cell Viability. The Prostate 66, 1292–1301 (2006).
54. Kim, J.-M. et al. Identification of Gastric Cancer–Related Genes Using a cDNA
Microarray Containing Novel Expressed Sequence Tags Expressed in Gastric
Cancer Cells. Clin. Cancer Res. 11, 473–482 (2005).
55. Pal, S. et al. Low Levels of miR-92b/96 Induce PRMT5 Translation and H3R8/H4R3
Methylation in Mantle Cell Lymphoma. EMBO J. 26, 3558–3569 (2007).
56. Hou, Z. et al. The LIM Protein AJUBA Recruits Protein Arginine Methyltransferase 5
To Mediate SNAIL-Dependent Transcriptional Repression. Mol. Cell. Biol. 28, 3198–
3207 (2008).
57. Leiper, J. et al. Disruption of Methylarginine Metabolism Impairs Vascular
Homeostasis. Nat. Med. 13, 198–203 (2007).
58. Haghikia, A. et al. Signal Transducer and Activator of Transcription 3-mediated
Regulation of miR-199a-5p Links Cardiomyocyte and Endothelial Cell Function in the
Heart: a Key Role for Ubiquitin-conjugating Enzymes. Eur. Heart J. 32, 1287–1297
(2011).
59. Tang, J. et al. PRMT1 Is the Predominant Type I Protein Arginine Methyltransferase
in Mammalian Cells. J. Biol. Chem. 275, 7723–7730 (2000).

22
60. Frankel, A. et al. The Novel Human Protein Arginine N-Methyltransferase PRMT6 Is
a Nuclear Enzyme Displaying Unique Substrate Specificity. J. Biol. Chem. 277,
3537–3543 (2002).
61. Liu, Q. & Dreyfuss, G. In Vivo and In Vitro Arginine Methylation of RNA-binding
Proteins. Mol. Cell. Biol. 15, 2800–2808 (1995).
62. Zhang, X. & Cheng, X. Structure of the Predominant Protein Arginine
Methyltransferase PRMT1 and Analysis of Its Binding to Substrate Peptides.
Structure 11, 509–520 (2003).
63. Weiss, V. H. et al. The Structure and Oligomerization of the Yeast Arginine
Methyltransferase, Hmt1. Nat. Struct. Mol. Biol. 7, 1165–1171 (2000).
64. Zhang, X., Zhou, L. & Cheng, X. Crystal Structure of the Conserved Core of Protein
Arginine Methyltransferase PRMT3. EMBO J. 19, 3509–3519 (2000).
65. Yue, W. W., Hassler, M., Roe, S. M., Thompson-Vale, V. & Pearl, L. H. Insights into
Histone Code Syntax from Structural and Biochemical Studies of CARM1
Methyltransferase. EMBO J. 26, 4402–4412 (2007).
66. Sun, L. et al. Structural Insights into Protein Arginine Symmetric Dimethylation by
PRMT5. Proc. Natl. Acad. Sci. (2011). doi:10.1073/pnas.1106946108
67. Cheng, Y., Frazier, M., Lu, F., Cao, X. & Redinbo, M. R. Crystal Structure of the
Plant Epigenetic Protein Arginine Methyltransferase 10. J. Mol. Biol. 414, 106–122
(2011).
68. Niewmierzycka, A. & Clarke, S. S-Adenosylmethionine-Dependent Methylation in
Saccharomyces Cerevisiae Identification of a Novel Protein Arginine
Methyltransferase. J. Biol. Chem. 274, 814–824 (1999).
69. Gui, S. et al. Investigation of the Molecular Origins of Protein-arginine
Methyltransferase I (PRMT1) Product Specificity Reveals a Role for Two Conserved
Methionine Residues. J. Biol. Chem. 286, 29118–29126 (2011).
70. Wooderchak, W. L. et al. Substrate Profiling of PRMT1 Reveals Amino Acid
Sequences That Extend Beyond the ‘RGG’ Paradigm†. Biochemistry (Mosc.) 47,
9456–9466 (2008).
71. Obianyo, O., Causey, C. P., Jones, J. E. & Thompson, P. R. Activity-Based Protein
Profiling of Protein Arginine Methyltransferase 1. ACS Chem. Biol. 6, 1127–1135
(2011).
72. Iberg, A. N. et al. Arginine Methylation of the Histone H3 Tail Impedes Effector
Binding. J. Biol. Chem. 283, 3006–3010 (2008).
73. Pal, S., Vishwanath, S. N., Erdjument-Bromage, H., Tempst, P. & Sif, S. Human
SWI/SNF-Associated PRMT5 Methylates Histone H3 Arginine 8 and Negatively

23
Regulates Expression of ST7 and NM23 Tumor Suppressor Genes. Mol. Cell. Biol.
24, 9630–9645 (2004).
74. Zurita-Lopez, C. I., Sandberg, T., Kelly, R. & Clarke, S. G. Human Protein Arginine
Methyltransferase 7 (PRMT7) Is a Type III Enzyme Forming ω-NG-Monomethylated
Arginine Residues. J. Biol. Chem. 287, 7859–7870 (2012).
75. Lee, J., Cheng, D. & Bedford, M. T. Techniques in Protein Methylation. Signal
Transduct. Protoc. (Dickson, R. C. & Mendenhall, M. D.) 195–208 (Humana Press,
2004). at <http://link.springer.com/protocol/10.1385/1-59259-816-1%3A195>
76. Milliman, E. J. et al. Recruitment of Rpd3 to the Telomere Depends on the Protein
Arginine Methyltransferase Hmt1. PLoS ONE 7, e44656 (2012).
77. Yu, M. C., Lamming, D. W., Eskin, J. A., Sinclair, D. A. & Silver, P. A. The Role of
Protein Arginine Methylation in the Formation of Silent Chromatin. Genes Dev. 20,
3249–3254 (2006).
78. Lakowski, T. M. & Frankel, A. Kinetic Analysis of Human Protein Arginine Nmethyltransferase 2: Formation of Monomethyl- and Asymmetric Dimethyl-Arginine
Residues on Histone H4. Biochem. J. 421, 253–261 (2009).
79. Tang, J., Gary, J. D., Clarke, S. & Herschman, H. R. PRMT 3, a Type I Protein
Arginine N-Methyltransferase That Differs from PRMT1 in Its Oligomerization,
Subcellular Localization, Substrate Specificity, and Regulation. J. Biol. Chem. 273,
16935–16945 (1998).
80. Pollack, B. P. et al. The Human Homologue of the Yeast Proteins Skb1 and Hsl7p
Interacts with Jak Kinases and Contains Protein Methyltransferase Activity. J. Biol.
Chem. 274, 31531–31542 (1999).
81. Fabbrizio, E. et al. Negative Regulation of Transcription by the Type II Arginine
Methyltransferase PRMT5. EMBO Rep. 3, 641–645 (2002).
82. Kirmizis, A. et al. Distinct Transcriptional Outputs Associated with Mono- and
Dimethylated Histone H3 Arginine 2. Nat. Struct. Mol. Biol. 16, 449–451 (2009).
83. Yost, J. M., Korboukh, I., Liu, F., Gao, C. & Jin, J. Targets in Epigenetics: Inhibiting
the Methyl Writers of the Histone Code. Curr. Chem. Genomics 5, 72–84 (2011).
84. Zhang, X. et al. Structural Basis for the Product Specificity of Histone Lysine
Methyltransferases. Mol. Cell 12, 177–185 (2003).
85. Couture, J.-F., Collazo, E., Brunzelle, J. S. & Trievel, R. C. Structural and Functional
Analysis of SET8, a Histone H4 Lys-20 Methyltransferase. Genes Dev. 19, 1455–
1465 (2005).
86. Xiao, B. et al. Structure and Catalytic Mechanism of the Human Histone
Methyltransferase SET7/9. Nature 421, 652–656 (2003).

24
87. Collins, R. E. et al. In Vitro and in Vivo Analyses of a Phe/Tyr Switch Controlling
Product Specificity of Histone Lysine Methyltransferases. J. Biol. Chem. 280, 5563–
5570 (2005).
88. Chu, Y., Yao, J. & Guo, H. QM/MM MD and Free Energy Simulations of G9a-Like
Protein (GLP) and Its Mutants: Understanding the Factors That Determine the
Product Specificity. PLoS ONE 7, e37674 (2012).
89. Couture, J.-F., Dirk, L. M. A., Brunzelle, J. S., Houtz, R. L. & Trievel, R. C. Structural
Origins for the Product Specificity of SET Domain Protein Methyltransferases. Proc.
Natl. Acad. Sci. (2008). doi:10.1073/pnas.0806712105
90. Del Rizzo, P. A. et al. SET7/9 Catalytic Mutants Reveal the Role of Active Site Water
Molecules in Lysine Multiple Methylation. J. Biol. Chem. 285, 31849–31858 (2010).
91. Xu, W. et al. A Methylation-mediator Complex in Hormone Signaling. Genes Dev.
18, 144–156 (2004).
92. Lacroix, M. et al. The Histone-Binding Protein COPR5 Is Required for Nuclear
Functions of the Protein Arginine Methyltransferase PRMT5. EMBO Rep. 9, 452–
458 (2008).
93. Feng, Q. et al. Biochemical Control of CARM1 Enzymatic Activity by
Phosphorylation. J. Biol. Chem. 284, 36167–36174 (2009).
94. Cao, Y., Mu, J.-J., Fang, Y., Yuan, Z.-Y. & Liu, F.-Q. Impact of High Salt
Independent of Blood Pressure on PRMT/ADMA/DDAH Pathway in the Aorta of Dahl
Salt-Sensitive Rats. Int. J. Mol. Sci. 14, 8062–8072 (2013).
95. Böger, R. H. et al. LDL Cholesterol Upregulates Synthesis of Asymmetrical
Dimethylarginine in Human Endothelial Cells Involvement of S-Adenosylmethionine–
Dependent Methyltransferases. Circ. Res. 87, 99–105 (2000).
96. Matsuguma, K. et al. Molecular Mechanism for Elevation of Asymmetric
Dimethylarginine and Its Role for Hypertension in Chronic Kidney Disease. J. Am.
Soc. Nephrol. 17, 2176–2183 (2006).
97. Chiarugi, P. & Cirri, P. Redox Regulation of Protein Tyrosine Phosphatases During
Receptor Tyrosine Kinase Signal Transduction. Trends Biochem. Sci. 28, 509–514
(2003).
98. Guccione, E. et al. Methylation of histone H3R2 by PRMT6 and H3K4 by an MLL
complex are mutually exclusive. Nature 449, 933–937 (2007).
99. Hyllus, D. et al. PRMT6-mediated Methylation of R2 in Histone H3 Antagonizes H3
K4 Trimethylation. Genes Dev. 21, 3369–3380 (2007).
100. Shi, Y. et al. Histone Demethylation Mediated by the Nuclear Amine Oxidase
Homolog LSD1. Cell 119, 941–953 (2004).

25
101. Chang, B., Chen, Y., Zhao, Y. & Bruick, R. K. JMJD6 Is a Histone Arginine
Demethylase. Science 318, 444–447 (2007).
102. Mantri, M. et al. Crystal Structure of the 2-Oxoglutarate- and Fe(II)-Dependent
Lysyl Hydroxylase JMJD6. J. Mol. Biol. 401, 211–222 (2010).
103.

Teerlink, T. ADMA Metabolism and Clearance. Vasc. Med. 10, S73–S81 (2005).

104. Cheng, D. et al. Small Molecule Regulators of Protein Arginine
Methyltransferases. J. Biol. Chem. 279, 23892–23899 (2004).
105. Lakowski, T. M., ’t Hart, P., Ahern, C. A., Martin, N. I. & Frankel, A. NηSubstituted Arginyl Peptide Inhibitors of Protein Arginine N-Methyltransferases. ACS
Chem. Biol. 5, 1053–1063 (2010).

26

CHAPTER 2
THE EFFECTS OF REDUCTION ON THE OLIGOMERIZATION, ENZYMATIC
ACTIVITY, AND SUBSTRATE BINDING OF
PROTEIN ARGININE METHYLTRANSFERASE 1 (PRMT1)
ABSTRACT
Protein arginine methyltransferase 1 (PRMT1) catalyzes the mono- and
dimethylation of protein arginine residues. Even though arginine methylation occurs on a
wide variety of protein substrates in many biological processes, regulation of PRMT1 is
not well understood. We report evidence of oligomeric state, activity, and substrate
binding differences between oxidized and reduced states of the PRMT1 enzyme. This
evidence introduces the exciting potential for an in vivo regulatory mechanism of PRMT1
during oxidative stress.
INTRODUCTION
Cellular regulation of the proteome can occur at one of four levels: DNA
transcription, RNA processing, RNA translation, and post-translational modification
(PTM). PTMs alter the function of existing proteins, often relaying a signal by inducing
protein-protein interactions, enhancing or inhibiting enzymatic activity, shifting cellular
localization, or increasing or decreasing protein stability. Protein methylation, one such
modification, is the addition of a methyl group to the side chain of specific amino acid
residues in a protein. Protein arginine methyltransferases catalyze the transfer of a
methyl group(s) from S-adenosylmethionine (AdoMet) to a guanidinium nitrogen(s) of an
arginine side chain on a protein substrate, resulting in monomethylarginine (MMA),
asymmetric dimethylarginine (ADMA) or symmetric dimethylarginine (SDMA). A variety
of biological pathways1–3 have been associated with arginine methylation and PRMTs
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are increasingly studied as pharmaceutical targets as methylation continues to be
implicated in many human diseases4–11. Surprisingly, very little information is available
regarding how PRMT1 activity is regulated.
Using quantitative kinetic and equilibrium measurements as well as gel filtration
chromatography, we have discovered that PRMT1 is susceptible to oxidative damage
which can be reversed by reductants such as dithiothreitol (DTT). Reduced and oxidized
states of PRMT1 have different activities and different oligomeric states.

This work

highlights the exciting potential that PRMTs are regulated by oxidative stress in vivo.
MATERIALS AND METHODS
Materials— S-Adenosyl-L-methionine was purchased from Sigma as a chloride
salt (≥80%, from yeast).

S-[Methyl-3H]-Adenosyl-L-methionine was purchased from

Perkin Elmer. The R3 peptide (GGRGGFGRGGFGGRGGFG) was synthesized by the
Keck Institute (Yale University) and purified to ≥95%. The lyophilized peptide was
dissolved in water and its concentration was determined by mass or by UV spectroscopy
(A280

nm=5,690

M-1cm-1). ZipTip®C4/C18 pipette tips were purchased from Millipore. TEV

was expressed and purified according to previous protocols12.
Plasmid generation—The His6-ratPRMT1 plasmid was previously generated13. To
create an enzyme construct with a cleavable His6-tag, a DNA segment coding for a
tobacco etch virus (TEV) cleavage site was designed with both N- and C-terminal NdeI
restriction sites. The NdeI restriction enzyme was then used to cut open the vector at an
NdeI site between the His6-tag and the enzyme coding sequence, and the designed TEV
insert ligated using the Quick LigationTM kit from New England Biolabs (Cat#
M2200S).The C101S and C342S variants were generated using the His tagged
ratPRMT1 (HrP1) plasmid as a PCR template for site directed mutagenesis using the
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QuikChange Lightning Kit (Stratagene) and sets of complementary oligonucleotide
primers spanning the desired site of mutation. To create constructs replacing all 11
cysteine residues with serines, properly coded DNA with N-terminal NdeI and C-terminal
BamHI restriction sites was ordered from GenScript. The HrP1 (His6-NdeI-ratPRMT1BamHI) and HTR (His6-TEV-NdeI-ratPRMT1-BamHI) vectors as well as the ordered cys
to ser insert DNA were double digested with NdeI and BamHI restriction enzymes, gel
extracted from a 0.8% agarose using the Quantum Prep Freeze ‘N Squeeze spin
columns from Bio-Rad (Cat# 732-6166), and ligated together using the Quick LigationTM
kit. All plasmids were transformed into a E.coli Dh5α cell line, resuspended in 5 mL liquid
2XYT culture and grown overnight at 37°C. Plasmids were purified using the Qiagen
Plasmid Mini Kit (Cat# 12123) and sequenced to confirm the correctness of the open
reading frame prior to protein expression.
Recombinant protein purification— E.coli BL21 cells carrying their respective
His6-tagged enzyme plasmids were grown in LB broth at 37°C. Protein expression was
induced at OD 0.6 with 0.5 mM IPTG for 24 hours at room temperature. Cells collected
via centrifugation were resuspended in wash buffer (50 mM sodium phosphate [pH 7.6],
and 5 mM (HTR) or 20 mM (HrP1) imidazole). Lysis was performed by sonication in
three 15-second cycles and the lysate clarified by centrifugation at 47,000xg for 20
minutes. The resulting supernatant was incubated with 1-6 mL Ni Sepharose 6 Fast Flow
resin (GE healthcare) rotating for 2 hours at 4°C. The binding reaction was pelleted at
700xg, the supernatant discarded, and the resin washed 4 times with 5 mM (HTR only),
4 times with 20 mM imidazole buffer, 7 times with 70 mM buffer, and lastly eluted in 6
washes with 250 mM imidazole buffer. The elutions were pooled, buffer exchanged by
dialysis into storage buffer (50 mM sodium phosphate [pH 7.6], and 10% glycerol),
concentrated to greater than 2 mg/mL, and beaded in liquid nitrogen for storage at
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negative 80°C. To generate cleaved constructs, half of the His6-TEV enzymes were put
into cleavage buffer (50 mM sodium phosphate, 1mM DTT, 2mM EDTA, 5% glycerol),
the TEV enzyme added (1:10 TEV:enzyme) and allowed to cleave with stirring overnight.
The cleaved enzyme was dialyzed into storage buffer, re-incubated with nickel resin
(removal of TEV and remaining His6-tag), and the subsequent supernatant treated the
same as the His6-tagged elutions. Enzyme cleavage and purity (>90%) was assessed
during and after purification using SDS-page. Protein concentrations were determined by
UV spectroscopy (A280 nm=54,945 M-1cm-1) and by the Bradford assay with bovine serum
albumin as a standard.
Kinetic assays of PRMT1 constructs— A sensitive methylation assay with
ZipTip®C4/C18 was used in testing the enzymatic activity under steady-state conditions12.
Enzyme activity was assessed at 37 °C in assays containing 100 nM PRMT1 construct,
2 μM AdoMet (1 μM [3H] AdoMet), 0.38 µM bovine serum albumin, 10 nM MTAN and
initiated by 200 μM peptide or 2 μM protein substrate. Reactions in the presence of DTT
were performed by pre-incubation of the reaction with 1 mM DTT for 10 minutes prior to
reaction initiation with substrate. At different time points, 5 µL samples were removed
from reactions and stopped in 6 µL of 6 M guanidinium hydrochloride. Samples were
then processed with ZipTip®C4/C18 pipette tips (for protein or peptide substrates,
respectively) to separate the unreacted [3H] AdoMet and the radiolabeled product.
Size exclusion chromatography— Gel filtration chromatography was performed
using a Superdex 200 column using a BioLogic LP chromatography system (Bio-Rad).
The column was equilibrated with 5 column volumes of running buffer consisting of 50
mM sodium phosphate, 150 mM NaCl, and 5% glycerol. All constructs were analyzed by
loading 250 µL of enzyme at a concentration of 20 µM and run at 0.4 mL/min for 30 mL.
An additional HTR sample, using a load concentration of 70 µM, was run to generate an
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improved chromatogram with a lower background (no change in the peak elution
volumes was detected).
Dissociation Constant Measurement by Intrinsic Fluorescence Quenching—
APC1 fluorimeter (ISS Corp, IL) was used for fluorescence measurements. For the
AdoMet affinity determinations, an excitation wavelength of 290 nm was used and
emission spectra were collected at 333 nm. The samples were measured using 1900 uL
samples containing 1.4 µM PRMT1 in buffer containing 50 mM sodium phosphate, pH
7.6, and 10% glycerol. Increasing concentrations from 2 to 60 µM AdoMet ligand were
added in 3-minute intervals.
Stopped-Flow Kinetic Measurements— Kinetic data were acquired with an
AutoSF2000 stopped-flow instrument (Kintek Corp., TX). The stopped-flow system was
configured with a two-syringe (2.5-mL) kinetic sample handling unit, a 20-μl flow cell
(with a 10-mm pathlength), and 2.5-mL stop syringe. Temperature control was achieved
through use of a Neslab RTE-101 water bath. Individual solutions containing 1 µM
PRMT1 and varied AdoMet concentrations (5-75 µM) were dispensed into the drive
syringes. Samples were excited at 290 nm and emission was monitored using a 350 nm
cut-off long pass filter. Data were collected using two time windows (1 sec and 9 sec)
with 2000 data points collected per window. Data was analyzed with KaleidaGraph
software using double exponential regression using the equation A1e^(-k1T) + A2e^(-k2T)
+ C, where A1 and A2 are the amplitudes of the first and second exponential phases and
k1 and k2 are the rates for the 2 phases.
RESULTS
The enzymatic activity of PRMT1 is influenced by reducing agents
DTT significantly enhances the enzymatic activity of His-rPRMT1— Dithiothreitol
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(DTT) is a common reducing agent used during purification and/or protein arginine
methylation assays. Studies using GST-PRMT2 and GST-PRMT7 indicate that DTT
significantly enhances the enzymatic activity14. Despite wide use and evidence
suggesting that DTT is required for maximal activity for some of the isoforms, the precise
effect(s) of DTT on the characteristics of the PRMT1 enzyme remain unclear. To
rationalize the need for DTT in PRMT1 methylation reactions, we first tested its effect on
the enzymatic activity of His6-tagged rat PRMT1 (HrP1). Pre-incubation of HrP1 with 1
mM DTT increased methyl transferase activity by 13-17-fold with the R3 peptide
substrate (Figure 2-1A), and by 5-fold with the HnRNP K protein substrate (data not
shown).
In order to better understand how DTT increased enzymatic activity, we preincubated PRMT1 with DTT and removed the DTT using a desalting column prior to the
methyltransferase reaction. The activity of the desalted HrP1 with the R3 peptide only
increased by 2-fold (Figure 2-1A), which demonstrated that the effect of DTT was
transient. Next we investigated the relationship between enzymatic activity and the
concentration of DTT. Methylation assays were performed with varied concentrations of
DTT ranging from 0.1 mM to 5 mM and a maximal rate enhancement at 1.5-2mM DTT
(apparent kcat = 1.91 min-1) was observed (Figure 2-1B).
Maximum PRMT1 activity requires a reductant— DTT has two potential methods
of action to increase PRMT1 activity: acting either as a reductant or as an intermediate
acceptor molecule in the methyl group transfer process. Methylation of the sulfhydryl
groups

in

DTT

was

previously

observed

with

small

molecule

plant

O-

methyltransferases15. Even though no DTT methylation was detected in our no substrate
control reaction (Figure 2-1A), we further tested this hypothesis by replacing DTT with an
alternative thiol-free reductant, Tris(2-carboxyethyl)phosphine (TCEP). HrP1 activity was
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Figure 2-1: The effect of reducing agents on the enzymatic activity of PRMT1. (A)
HrP1 methylation rates assayed in the absence () and presence of DTT () or TCEP
() and after desalting following a 10-minute pre-incubation with DTT (). A control
reaction with no substrate was also run (). (B) The apparent kcat measured as a
function of DTT concentration. (C) Structures of DTT, TCEP, and S-adenosyl
methionine. (Note, this work has previously appeared as part of Shanying Gui’s Ph.D.
dissertation).

examined using 1mM TCEP and the R3 peptide substrate and the rate enhancement
observed was identical to that observed using 1mM DTT. We conclude from this study
that DTT is acting as a reductant and not acting as a methyl group transfer intermediate.
The PRMT core is responsible for the reductant dependent activity increase
DTT increases the activity of both His6-tagged and un-tagged PRMT1 enzymes—
Several different affinity tags are used for PRMT1 purification and variable methylation
rates have been observed16–18. We questioned whether the His6-tag was influencing our
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observed rate changes upon adding DTT. We created a His6-tagged, tobacco etch virus
(TEV) cleavable, rat PRMT1 construct (HTR) in order to purify a cleaved, and therefore
un-tagged enzyme (cHTR), for kinetic analysis with DTT. Attempts to express a tagless
version of PRMT1 resulted in unstable protein which lost activity rapidly (data not
shown). Several biological replicates of HTR and cHTR all exhibited the observed
enzymatic rate enhancement upon the addition of 1mM DTT (Figure 2-2).
Incubation with DTT and EDTA is responsible for improved cHTR activity— The
protocol for TEV cleavage included 1mM DTT and 2 mM EDTA present in the dialysis
buffer during the overnight cleavage process. We surmised from this that the lessened
DTT effect on cHTR activity was likely due to the overnight dialysis during cleavage, and

Methyl Groups Transfered (µM)

the subsequent purification, removing DTT, allowed only a small amount of oxidation to
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Figure 2-2: The effect of DTT is independent of the His6-tag. Enzymatic activity of
HTR, cHTR, and dialyzed HTR assayed with the R3 peptide substrate in the absence
(, , ) and presence of DTT (, , ) respectively.
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occur prior to storage. To test this theory, we again purified both the HTR and cHTR
enzymes and treated the HTR enzyme to same overnight dialysis step cHTR received.
Methylation assays of these newly purified HTR and cHTR enzymes revealed no
significant rate enhancement upon addition of DTT (Figure 2-2). We conclude from
experiments thus far that PRMT1 is susceptible to reversible oxidative impairment,
independent of the His6-affinity tag.
Reduction with DTT alters the oligomeric state of PRMT1
Feng et al.16 introduced the idea that changing the oligomeric state of PRMT1
affects enzymatic activity. Since PRMT1 reduction results in increases in activity, we
hypothesized that the reductant may be changing the oligomeric state of the enzyme.
We assessed our hypothesis using size exclusion chromatography pre- and postreduction of the enzymes (Figure 2-3). Unreduced HTR migrates over a broad range of
oligomeric states, with the majority of the protein existing in oligomers that migrate at
molecular weights above 660 kDa. As a reference, PRMT1 is thought to be active as an
80 kDa dimer at minimum17. Overnight incubation with 1mM DTT resulted in a shifting of
oligomeric states, with the majority of oligomers migrating below 660 kDa. Addition of
2mM EDTA to the overnight DTT incubation resulted in a much greater shift towards a
homogeneous oligomeric state migrating between 350 and 450 kDa. The cHTR enzyme
migrated as two peaks, a small void volume peak, and a large peak at roughly the
samemigration volume as the shifted HTR peaks. Additionally, overnight treatment of
cHTR with 1mM DTT had no detectable effect on the migration of cHTR. The general
decrease in siz e in the presence of a reductant, combined with the previously discussed
activity data, suggest that the oligomeric differences between HTR and cHTR are not
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Figure 2-3: Oligomeric state assessment via size exclusion chromatography.
(A) HTR in the absence of DTT, (B) HTR incubated overnight with 1mM DTT, (C)
HTR incubated overnight with 1mM DTT and 2mM EDTA, (D) cHTR in the absence
of DTT, (E) cHTR incubated overnight with 1mM DTT and 2mM EDTA. Molecular
weight standards: 660kDa (1) 440kDa (2), 200kDa (3), and 66kDa (4).

due to the His6-tag, but due to cHTR’s treatment in overnight dialysis in the presence of
DTT/EDTA during the cleavage process.
The reductant-dependent effects on PRMT1 require a cysteine(s) residue
C101 and C342 are not responsible for reductive effects— The most common
mechanism for oxidative damage is the oxidation of cysteine residues. As such, we
began our investigation into what residues of the PRMT core are undergoing redox
chemistry by mutating cysteines. To select cysteines for mutation, we searched the rat
PRMT1 crystal structure (see Figure 2-8) for cysteine residues capable of undergoing
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Figure 2-4: Enzymatic activity of single cysteine variants with the R3 peptide
substrate. C101S and C342 assayed in the absence (,) and presence of DTT
(,) respectively.

oxidation and found that cysteines 101, 208, 232, 254, 342, and 346 are all solvent
accessible. Cysteine 101 resides on the far edge of the AdoMet binding pocket and
directly interacts with the adenine ring structure of AdoMet. A recent quantitative
reactivity profiling study identified C101 as hyper-reactive with 4-hydroxyl-2-nonenal
(HNE)19, indicating that C101 may be prone to oxidation. Surprisingly, mutation of C101
to serine results in a construct mimicking wild type activity, including the response to
DTT (Figure 2-4). Closer evaluation of our rat PRMT1 M48L crystal structure showed
increased electron density around cysteine 342, suggesting possible oxidation of the
thiolate moiety to a reducible sulfenate. Although this residue is relatively removed from
the active site, it has been suggested that residues distant from the active site can
regulate PRMT substrates specificity20. The C342S variant also mimicked wild type
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enzymatic activity, including the DTT enhancement (Figure 2-4A). The similarities
between the wild type enzyme and C101S/C342S variants indicate that neither is
culpable for the effects caused by oxidation/reduction.
Mutation of all cysteine residues in the PRMT1 enzyme negates the DTT effect—
We took a broader approach to evaluate whether any cysteine residues were
responsible for the effect of oxidation/reduction and expressed both cleavable and uncleavable cysteine to serine variant rat PRMT1 enzymes (HTRcys- and HrP1cys-). The
His6-tagged and cleaved enzymes were assayed with the R3 peptide and exhibited no
enhanced activity upon pre-incubation with DTT (Figure 2-5A). In addition to activity
measurements, the oligomeric state was assessed by size-exclusion chromatography
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Figure 2-5: Enzymatic activity and oligomeric state of the cysteine to serine
PRMT1 variant enzymes. (A) Enzymatic activity of HrP1cys-, HTRcys-, and cHTRcyswith the R3 substrate assayed in the absence (, , ) and presence of DTT (, ,
) respectively. (B) Size exclusion chromatography comparing cHTR (A) and HTRcys(B). Molecular weight standards: 660kDa (1) 440kDa (2), 200kDa (3), and 66kDa (4).
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(Figure 2-5B). The cysteine-less PRMT1 variants all exhibited migration patterns similar
to that of the maximally active cHTR and HTR (pre-incubated with DTT). We conclude
from these observations that one (or more) cysteines are involved in the redox chemistry
causing increased activity after incubation with a reductant.
AdoMet shows moderately increased binding affinity for PRMT1 in the presence of
DTT
The dissociation constant (Kd) is mildly decreased by reduction— After using
steady state kinetics to identify that a cysteine residue(s) was responsible for the overall
effect of DTT on enzymatic activity, we sought to elucidate details of the kinetic
mechanism of PRMT1 that are affected by reduction. We proceeded to determine the
dissociation constant (Kd) of AdoMet for PRMT1 by using a previously derived procedure
to measure intrinsic tryptophan fluorescence quenching of PRMT1 upon the addition of
ligand. The Kd values of AdoMet for HTR in the absence and presence of DTT were
similar (1.7-fold greater in the absence of DTT, Figure 2-6) but not different enough to
explain our observed changes in enzymatic activity.
The association constant of AdoMet for PRMT1 is dramatically increased in the
presence of DTT— The intrinsic fluorescence quenching experiment measures the Kd of
AdoMet for PRMT1 at equilibrium. Previous attempts to determine the binding rate
constant of AdoMet to the un-cleavable His6-tagged ratPRMT1 enzyme proved
unsuccessful in the absence of DTT. This inability to collect usable data combined with
the slight increase in Kd in the presence of DTT prompted us to investigate if DTT was
affecting the rate at which AdoMet binds to PRMT1. Using a more sensitive stopped-flow
fluorimeter we were able to collect fluorescence quenching data with HTR both in the
absence and presence of DTT (Figure 2-7A). Interestingly, addition of DTT to the
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Figure 2-6: The effect of DTT on the dissociation constant (kd) of AdoMet for
PRMT1. Fluorescence quenching of HTR in the absence () and presence () of DTT.

reactions resulted in additional fluorescence quenching. These quenching curves were
fit using double exponential regression to calculate k1 and concentration of AdoMet (µM)
vs. k1 (s-1) was plotted (Figure 2-7B). This plot shows that the average association
constant of AdoMet for PRMT1 is 21-fold faster in the presence of DTT. While the rate of
AdoMet binding to PRMT1 is still faster than the reported methyl transfer step, it may still
act in a combinatorial fashion with other reaction steps which result in the slowed overall
reaction rate (kcat) we observe under steady state conditions when the enzyme becomes
oxidized.
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Figure 2-7: The effect of DTT on the on and off rates of AdoMet binding to
PRMT1. (A) Stopped-flow fluorescence quenching of HTR by 0 (grey) and 10 µM
(colored) AdoMet in the absence (blue) and presence (red) of DTT. Traces of a buffer
only sample (lightest grey) and the two HTR samples with 0 µM SAM all overlay and
are colored grey for clarity. (B) Plot of the varied AdoMet concentration vs. the
calculated k1 (on rate) of AdoMet to HTR in the absence () and presence () of DTT.

DISCUSSION
Our understanding of the importance of PRMTs in biology and human disease
has greatly increased during the past decade. Arginine methylation has been observed
in cardiovascular disease21–23 and cancer8,24–29 suggesting PRMTs as a good target for
therapeutic drug development to treat disease. Regulation of enzymatic activity is
essential for proper functioning of cellular processes. Protein methylation is carefully
regulated by protein interactions30–33, active site residues17,34,35, product inhibition36, and
post-translational modifications37,38. In this work, we demonstrate changes in quaternary
structure and enzymatic activity in reductive conditions, thereby suggesting a potential
mechanism of regulation during oxidative stress in vivo.
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The enzymatic activity and oligomeric state of PRMT1 are changed by
reduction— The quaternary structure of PRMTs as it relates to enzymatic activity has
been a source of great study in the PRMT1 field and it is accepted that PRMT oligomers
are required for enzymatic activity17,39,40. Feng et al.16 used chemical crosslinking to
investigate the effect of enzyme concentration on oligomeric state. Using a concentration
range of 0.012 µM to 1.56 µM enzyme, an overall increase in oligomeric state was
observed as concentration increased. More specifically, the quantity of mono- and dimers decreased while the quantity of oligomers increased, causing an oligomeric
rearrangement which slowed at ~0.5 µM enzyme.
At first, our studies showing that reducing PRMT1 decreased the overall
oligomeric mass and increased enzymatic activity may seem to conflict with this previous
study. However, our oligomeric state studies are performed at a concentration above the
observed maximal transition state, and our size-exclusion chromatography observations
showed that the reduced PRMT1 enzyme corresponded to a molecular weight range
(120-450 kDa) similar to other in vitro and in vivo studies17,26,41. Upon closer examination
of the western blot performed by Feng et al.16, it is observed that there are oligomeric
states ranging from monomers at 42 kDa to molecular weights greater than hexamers at
250 kDa. Ultimately, our work is consistent with previous observations that a higher
order oligomeric state is required for optimal enzymatic activity, not to be confused with
the massive oligomeric state observed in oxidative conditions. In addition to the previous
observations, we show evidence, through our work in non-reducing and reducing
environments, that this dynamic and complex system has great potential to be regulated
by oxidative stress in vivo.
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Figure 2-8: The structure of the rat PRMT1 enzyme. PDB:1OR8 Highlighted are the
six solvent accessible cysteine residues (green), the three buried cysteine residues
(red), the product SAH (yellow), the PRMT1 enzyme (grey), and a surface
representation of the second monomer (light blue).

Cysteine oxidation/reduction regulates PRMT activity in vitro—Cysteine residues
contain a thiol moiety in their side chain well known to undergo oxidation and reduction
in physiological conditions. At lower concentrations, reactive oxygen species can behave
as

signaling

molecules,

and

have

been

shown,

through

protein

cysteine

oxidation/reduction, to promote both cell proliferation42 and apoptosis43. Of the 11
cysteine residues found in PRMT1, six are solvent accessible in the rat PRMT1 structure
(Figure 2-8) and therefore have the potential for participating in redox chemistry.
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Unfortunately, the two cysteine residues we selected, C101 and C342S, were not
responsible for changes in activity and oligomeric state. However, we have shown
through the use of cysteine-less PRMT1 enzymes, which have approximately half of wild
type activity but no longer respond to reduction, that a cysteine residue(s) is responsible
for the observed redox effects. To address what type of cysteine oxidation is responsible
for the observed effects, we first observed from the crystal structure that the only
cysteine likely to hinder AdoMet binding was C101, due to its proximity to, and direct
interaction with, the benzene ring in the adenosine portion of the molecule. Since C101S
is still redox sensitive, we propose that the oxidization is most likely a disulfide bond
formation, possibly at C254, as opposed to formation of a sulfenic, sulfinic, or sulfonic
acid moiety on the thiol group of a cysteine residue side chain. Cysteine 254, observed
as a disulfide between dimers in the rat PRMT1 crystal structure, was previously
mutated to alanine to assess the relevance of the disulfide bond. Both oligomeric state
and activity were similar when comparing the wild type enzyme to the C254A variant. In
retrospect however, the C254 residue still seems like a likely candidate for
oxidation/reduction chemistry because the C254A experiments were conducted in the
presence of a reductant, masking any potential oxidative effect that may have been
observed.
Oxidation and reduction is a potential regulator of the rate limiting step in PRMT1
methylation— Understanding the mechanism of PRMT1 has been the work of several
groups16,44,45. Feng et al.16 reports that methyl transfer is the rate limiting step of the
PRMT1 mechanism (in the presence of DTT). Our enzyme as expressed and purified
over nickel resin, devoid of any DTT, may mimic an enzyme which has undergone mild
in vivo oxidative stress conditions. PRMT1 prepared in these in vitro conditions exists in
a state in which the rate of AdoMet binding is impaired greater than 20-fold. While the
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rate of AdoMet binding to PRMT1 (>5.8 s-1) is still faster than the reported methyl
transfer step (0.022 s-1), it may be that DTT induces rate differences in other steps of the
mechanism, including methyl transfer.
CONCLUSION
Our data, combined with other studies, indicates that oxidative stress conditions
may, through a cysteine oxidation, restructure PRMT1 into an unordered, massive
oligomeric state with an impaired ability to efficiently bind AdoMet. Furthermore, PRMT1
activity, in a state where AdoMet binding is rate limiting, will be more susceptible to
changes in cellular concentrations of AdoMet.
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Protein arginine methylation is an abundant post-translational modification
catalyzed by protein arginine methyltransferases (PRMTs). Arginine methylation plays
important roles in a variety of cellular pathways and human diseases. PRMT1, the
predominant PRMT, catalyzes approximately 85% of all protein arginine methylation in
vivo. While many details of how PRMT1 functions have been uncovered through the
past two decades, there are many details which remain unclear, including how arginine
methylation is regulated, how PRMT1 binds substrates, and what role PRMTs play in
RNA surveillance. Our recent data presented in this thesis showed that reduction of the
PRMT1 enzyme, following recombinant expression and purification, changes both
enzymatic activity and oligomeric state. A cysteine residue(s) was found to be
responsible for the observed redox chemistry in PRMT1 and at least one parameter in
the kinetic mechanism, S-adenosylmethionine (AdoMet) binding, was faster with a
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reduced enzyme. This work suggests exciting potential for the regulation of PRMTs in
vivo by oxidative stress.
In addition to studying the effects of reduction/oxidation on PRMT1, a foundation
for future experiments was laid. These experiments investigate substrate recognition by
PRMTs and what the role arginine methylation may play in RNA processing and
surveillance. To better understand how PRMTs selectively bind a wide variety of
substrates, I have designed and preliminarily characterized several Hmt1 (the S.
cerevisiae homologue of PRMT1) variants. These variants will be used for crystallization
trials of a homogeneous complex, containing Hmt1, AdoMet, and a peptide substrate,
capable of revealing specific chemical interactions between Hmt1 and the peptide
substrate. To further our understanding of Hmt1’s role in RNA processing and
surveillance, particularly in RNA degradation pathways, I extracted yeast RNA from both
wild type and Hmt1-null cells. The RNA was probed using a S. cerevisiae whole-genome
microarray. This analysis revealed that Hmt1 exhibits statistically significant effects in
several broad areas including molecular function, biological processes, cellular
components, and some KEGG pathways. The presented studies have revealed the
exciting potential for an in vivo regulatory mechanism of PRMT1 and each study is
primed for further investigation both in vivo and in vitro.
(85 pages)
CHAPTER 3
IDENTIFICATION AND CHEMICAL CHARACTERIZATION
OF THE BINDING INTERFACE(S) BETWEEN
hnRNP METHYLTRANSFERASE 1 (Hmt1) AND ITS SUBSTRATES
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INTRODUCTION
Cellular communication is essential for life. One way cells communicate is
through post-translational modifications. Protein arginine methylation has become a
prominent player in signal transduction and protein regulation in eukaryotic cells1–8.
There are 9 PRMTs that catalyze arginine methylation, using S-adenosylmethionine
(AdoMet) as a methyl donor, to form monomethylarginine (MMA), asymmetric
dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) on protein substrates.
Type I PRMTs represent the majority of methyltransferases and are capable of
catalyzing MMA and ADMA formation. Type II PRMTs produce both MMA and SDMA,
and type III PRMTs produce only MMA. Which form of arginine (MMA, ADMA, SDMA) is
produced has the potential to yield significant differences in biological response9–11.
These differing responses indicate that controlling arginine methylation, like other
post-translational modifications such as phosphorylation, is important for proper cellular
function. The methods of control include substrate specificity, the type of methylation
(MMA, AMDA, and SDMA), and the amount of methylation. While the mechanism of
PRMTs has been studied, there is a substantial lack of information explaining how
PRMT targets are recognized. In Saccharomyces cerevisiae, the human PRMT1
homologue hnRNP methyltransferase 1 (Hmt1), plays a role in regulating RNA-binding
proteins during the metabolism of nuclear pre-mRNA12. In addition to understanding how
methylation functions in biological pathways, enzyme specific and substrate specific
inhibitors for PRMTs will be of great value to the medical community in treating
conditions and diseases such as several types of cancer, muscular dystrophy,
amyotrophic lateral sclerosis (ALS), cardiovascular disease, diabetes mellitus, kidney
failure, chronic pulmonary disease, coronary heart disease, and renal failure13.
Inhibitors of PRMT1 can imitate AdoMet (cofactor), imitate a protein substrate, or
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interfere with substrate binding. AdoMet is a widely used biological cofactor, thus
creating AdoMet analogues, while valuable in vitro, may have limited in vivo significance
as this type of inhibitor is likely lack specificity for arginine methylation alone. Creating
peptide mimics overcomes the barrier of enzyme specificity, but introduces the common
hurdle of efficient and effective drug delivery. Several inhibitors are known which use
both these mechanisms and have arginine methyltransferase specificity, yet
identification of a single PRMT isoform inhibitor continues to be a challenge 14,15,16. A
novel approach to this important problem is to use in silico modeling to identify small
molecule inhibitors that would block substrate binding at a site other than the active site.
It is expected that this type of inhibitor would not only show isoform specificity, but also
block the methylation of specific protein substrates. In order for this approach to be
taken, a knowledge gap must be closed by identifying residues responsible for chemical
interactions at the PRMT:substrate interface(s).
Even with several solved PRMT crystal structures, one of which includes a bound
peptide substrate (a fibrillarin mimic, R3), the molecular mechanism(s) by which PRMTs
recognize their substrates remains unclear17,18. This lack of clarity stems from difficulty
obtaining crystals for structural analysis and from poor electron density data of the
bound peptide substrate in the crystal structure. In the rat PRMT1 structure, the electron
densityor the enzyme is clear, with exception of the N-terminal 40 amino acids which
appear mobile across all PRMT structures; however only electron density for the
backbone of the peptide substrate is visible. To add to the confusion, there is electron
density for the peptide backbone in three locations, or grooves, indicating multiple
substrate binding modes (Figure 3-1). In order to elucidate chemical interactions
between peptide substrate and enzyme, we are combining surface mutagenesis in the
grooves with carefully constructed asymmetric peptide substrates to create an
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enzyme:substrate complex that is sterically forcedinto a single homogeneous
conformation (Figure 3-1). My work has yielded eight purifiable variant Hmt1 proteins,
and preliminary enzymatic activities of all nine enzymes (variants and wild type) with
each of the three asymmetric peptides, are presented.
MATERIALS AND METHODS
Mutagenesis and purification—The pET15b vector coding for His6-tagged WTHmt1 expression was used as a template for site-directed mutagenesis with the
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Figure 3-1: Depiction of four possible HMT1:peptide binding modes. (A) A top
down view of HMT1 crystal structure with the R3 peptide superimposed from the rat
PRMT1 structure. Note, only four of ten possible binding modes are shown.Grey,
HMT1, Yellow, S-adenosylhomocysteine (AdoHcy), Red, R3 peptide backbone as
spheres, active site arginine as sticks. (B) Cartoon of HMT1 and the R3 peptide
bound with the central arginine in the active site (C) HMT1 with the N-terminal R3
arginine in the active site. (D) HMT1 with the c-terminal R3 arginine in the active site.
(E) Alternative binding of HMT1 with the c-terminal R3 arginine in the active site.
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QuikChange Lightning Kit (Stratagene) and sets of complementary oligonucleotide
primers spanning the 8 desired sites of mutation. After PCR, the plasmids were
transformed into a E.coli Dh5α cell line, resuspended in 5mL liquid 2XYT culture and
grown overnight at 37°C. Plasmids were purified using the Qiagen Plasmid Mini Kit
(Cat# 12123) and sequenced to confirm the correctness of the open reading frame prior
to protein expression. The His6-tagged WT-Hmt1 enzyme and all eight variants were
purified as described in Chapter 2.
Kinetic assays of Hmt1 constructs— A sensitive methylation assay with
ZipTip®C4/C18 was used in testing the enzymatic activity under steady-state conditions19.
Catalytic activities were assessed at 37 °C in assays containing 100 nM PRMT1
construct, 2μM AdoMet (1 μM [3H]AdoMet), 10 mM MTAN and initiated by 200 μM of the
peptide substrates (R3, RKK, KRK, or KKR). At different time points, 5 µL samples were
removed from reactions and stopped in 6 µL of 6 M guanidinium hydrochloride. Samples
were then processed with ZipTip®C4/C18 pipette tips (for protein or peptide substrates,
respectively) to separate the unreacted [3H] AdoMet and the radiolabeled product.
RESULTS AND DISCUSSION
Creating tools to investigate molecular interactions
Hmt1 variant design— In order to investigate how PRMTs target substrates, we
need to identify the surface(s) and residues involved in the enzyme:substrate interface.
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Figure 3-2: Considerations for residue
selection for mutagenesis. (A) HMT1
with the R3 peptide (green) and bound
SAH (yellow), modeled on top of the
enzyme’s electrostatic surface. (B)
Outward facing resides (red) in binding
groove one of Hmt1 (light grey) to be
considered for size. (C) Conservation in
putative peptide binding groove one,
where
red
residues
are
strictly
conserved, pink are slightly conserved
and cyan residues are un-conserved.

We decided to approach this problem using site-directed mutagenesis and three
asymmetric peptide substrates to limit peptide binding to a single mode. To begin design
of the Hmt1 variants, we first aligned the crystal structure of PRMT1 containing the
partial density of a bound peptide (R3) (PDB ID: 1OR8) with the crystal structure of Hmt1
(PDB ID: 1G6Q). The R3 peptide backbone was then modeled onto the Hmt1 structure.
When selecting residues for mutagenesis we took into account residue conservation
between rat PRMT1 and yeast Hmt1, residue charge, and side chain size (Figure 3-2).
Residue conservation is an important selection tool because rPRMT1 and Hmt1 are
capable of sharing cross species protein substrates. Residue charge was used to select
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residues in order to interrupt potential ionic interactions. Small side chain residues along
the bottom of the groove were chosen as targets to increase the side chain size and
thereby sterically hinder peptide binding.
The residues selected include: T40Y and V41E, to change a small hydrophobic
residue into a large polar/charged residue; D145G, to eliminate a negative charge that
may interact with positive residues in the peptide; D145W, to eliminate charge and
sterically block the binding to groove 1; N320A, assessing the importance of the only
conserved residue in groove 2; D152A, again eliminating a negative charge possibly
interacting with the peptide; and lastly, D152K, to reverse the potentially interacting
negative charge.
Asymmetric peptide design— Three peptides (RKK, KRK, and KKR, see Table 31) were strategically designed from the R3 peptide sequence, a mimic of the native
protein substrate fibrillarin20,21. In these peptides, two of the three arginines were
removed and the remaining arginine was positioned in three locations relative to the Nterminus of the peptide. This design creates three peptides that are asymmetric and
unidirectional. Our working hypothesis is that Hmt1 can only bind peptides in a
unidirectional orientation. In combination with mutations to block peptides from binding in

Table 3-1: Sequences of the designed peptide substrates.
Peptide Name

Peptide Sequence

R3 (RRR)

AcGGRGGFGRGGFGGRGGFG

RKK

AcGGRGGFGKGGFGGKGGFG

KRK

AcGGKGGFGRGGFGGKGGFG

KKR

AcGGKGGFGKGGFGGRGGFG

56
different grooves, we hope to uncover a variant/peptide combination capable of
homogenous crystallization which should reveal specific molecular interactions between
the peptide and Hmt1.
Comparing wild type Hmt1 to variant Hmt1 activities
Our hypothesis— Our first method of identifying which Hmt1 variants may be of
use in crystal structure trials is to assess the enzymatic activity with the asymmetric
peptides. In theory, if peptides do bind in multiple modes, each variant should be
capable of methylating the R3 peptide. Variants which lack the ability to methylate R3
indicate either acomplete loss of enzymatic activity and/or improperly folded protein,and
while not useful for this enzyme:substrate interaction study, these variants will identify
important residues for protein structure stability and/or catalysis. Our goal is to uncover a
combination of variants, in different grooves, which methylate the R3 peptide, but exhibit
inhibited methylation of only one of the asymmetric peptides. Take for example, a
scenario in which a mutation in groove 1 allows methylation of all the peptides except
RKK, and a mutation in groove 3 allows methylation of all the peptides except KKR.
These two mutations could then be combined in a double variant which blocks binding of
peptides in both groove 1 and groove 3. We would thus expect this double variant to
only methylate the R3 and KRK peptides, implying formation a single binding mode. This
double variant and the R3 and/or KRK peptides could be put into crystal trials, expecting
that the increased homogeneity of the complex would result in a structure that reveals
detailed atomic contacts between the enzyme and peptide substrate.
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Preliminary enzymatic activity screening— Initially, wild type Hmt1 and each of
the eight variants were purified and assayed with R3 and RKK (Figure 3-3). Additionally,
Hmt1 and five variants (D152A, D152K, N302A, T40Y, and V41E) were purified again
and assayed in duplicate with all four peptides (R3, RKK, KRK, and KKR) (Figure 3-3).
Unfortunately many purifications of the wild type Hmt1 enzyme have resulted in varied
enzymatic activities. This lack of repeatability in wild type activity makes comparison of
each variant to wild type difficult. The wild type-enzyme only weakly methylates the RKK
or KRK peptide substrates, but it is unclear if this lack of activity is due to substrate
preference or to preparative issues. Due to time constraints and thus a lack of a
complete data set, there are not yet any apparent combinations of variants of which a
double variant can be created. The V41E variant has very low activity with all the
peptides, indicating that the larger charged residue change is disrupting turnover. The

Methyl Groups Transferred (µM)

0.007
0.006
0.005
0.004
0.003
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0
FL-HMT1 D145G D152A N320A

T40Y

D145Y D152K

V41E

R317A

Figure 3-3: Enzymatic activities of the wild type and variant Hmt1 enzymes.
Enzymes were assayed with all four peptides: R3 (red), RKK (blue), KRK (green),
and KKR (grey).

58
D145Y variant exhibited enzymatic activity 2- to 50-fold greater than the other variants
with the R3 and RKK peptides and would be a good variant to assay with KRK and KKR
to test for a loss of activity.
Inconsistent wild type activity needs to be corrected— Before proceeding with
additional experiments investigating these variants, the variation in wild type Hmt1
enzymatic activity needs to be eliminated. A recent study revealed that Hmt1 can be
phosphorylated in vivo, on serine 9, and that this event is required for oligomerization
and activity22. They also observed that mutation of serine 9 to glutamate (S9E) mimics
phosphorylated enzyme and restores oligomerization and activity in vivo. The unknown
phosphorylation state of serine 9 may be one contributing parameter to the observed
inconsistency in Hmt1 enzymatic activity. In order to address this inconsistency, we need
to generate a S9E variant in our lab and assess its in vitro enzymatic activity. If multiple
purifications of the S9E variant yield consistent enzymatic activity, I would recommend
this mutation to be made on each of my variants in order to better mimic in vivo
conditions and make wild type Hmt1 more comparable with the variant enzymes.
Unfortunately, until this wild type issue is resolved, the usefulness of the current
mutations is limited and no significant conclusions have been drawn.
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CHAPTER 4
WHOLE GENOME MICROARRAY ANALYSIS OF TOTAL
RNA LEVELS IN WILD TYPE AND Hmt1-Null S. Cerevisiae CELL LINES
INTRODUCTION
RNA binding proteins (RBPs) are critical to the success of many steps of RNA
processing. Many of these proteins undergo post-translational modifications (PTMs),
such as phosphorylation and methylation, which may regulate their interactions with
RNA. In Saccharomyces cerevisiae, hnRNP methyltransferase 1 (Hmt1) mediated
methylation has been shown to be important in RNA surveillance and transport1–4. The
hnRNPs nuclear protein localization 3 (Npl3), heterogeneous nuclear ribonuclear protein
1 (Hrp1), and nuclear polyadenylated RNA binding 2 (Nab2) are all RBPs involved in
RNA transport and are methylated by arginine methylation implicating Hmt1 as one
mechanism of regulating RNA export5–7. In addition to export, RNA can be tagged for
degradation by the addition of a short poly(A) tail to the 3’ end. A poly(A) polymerase
(Trf4 or Trf5), a putative RNA-binding protein (Air1 or Air2), and a helicase (Mtr4) make
up the TRAMP complex which identifies RNA substrates and applies poly(A) tails8. The
TRAMP complex acts on a wide range of substrates including tRNAs, snoRNAs,
snRNAs, ncRNAs, rRNAs, some mRNAs, and cryptic unstable transcripts9. The Air1 and
Air2 proteins bind Hmt1 and inhibit its activity, possibly regulating RNA transport through
regulation of the RBPs10. The association of Air1 or Air2 with Hmt1 introduces the
concept of a role of arginine methylation in RNA processing on non-coding RNAs
(ncRNA).
To further understand the role of arginine methylation in global RNA surveillance,
we sought out exploratory techniques capable of monitoring RNA levels. A previous
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systems biology approach was taken to study Hmt1’s role in the genome-wide
localization profiles of its substrates. During this study, wild type (Hmt1) versus Hmt1null (Hmt1-/-) yeast cells were examined for changes in global mRNA levels analysis
with a full-length cDNA microarray1. Interestingly, gene expression of 64 genes was
altered greater than 2-fold by the loss of Hmt1. A separate study investigating the role of
the exosomal proteins Lrp1 (Rrp47) and Rrp6 (an exonuclease) in genome-wide mRNA
degradation used the transcriptional inhibitor thiolutin to halt RNA production in wild type
(Lrp1) and Lrp1-null (Lrp1-/-) yeast cells11. After thiolutin treatment, the RNA already
produced is given to 45 minutes degrade, then the RNA abundance changes (wild type
vs Lrp1-null) are assayed using a whole-genome microarray, which changes directly
reflect changes in RNA degradation due to the absence of the Lrp1 gene. We reasoned
that we could expand upon the current data, which reflects the loss of Hmt1 on mRNA
under equilibrium conditions, by combining these two techniques. In addition, because of
Hmt1’s known associations with many proteins involved in RNA surveillance and
transport, we adapted our reverse transcription technique to include not only mRNA, but
any RNAs (ncRNA, tRNAs, snoRNAs, snRNAs, ncRNAs, rRNAs) in the cell lysate.
MATERIALS AND METHODS
Growth conditions— Wild type S. cerevisiae and Hmt1 -/- cells were generously
received from Dr. Michael Yu at the University of Buffalo, and kept at -80°C. A swab of
each cell line was grown on YEPD media plates for 48 hours at 30°C. Three colonies of
each cell type were picked and grown separately in 50 mL YEPD liquid culture for
shaking for approximately 8 hours at 30°C. At OD .6, 4 µg/mL thiolution was added and
incubated for an additional 45 min, following which the cells were pelleted at 3,000xg,
fast frozen in liquid nitrogen, and stored at -80°C.
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Hot phenol RNA extraction— Frozen cells were thawed on ice, resuspended in
residual liquid, and transferred to a micro centrifuge tube. The cells were pelleted at
14,000 RPM at 4°C and the supe discarded. The pellet was resuspended in 500 µL TES
(10 mM Tris [pH 7.5], 10 mM EDTA, 5% SDS, RNase-free) and 500 µL acid phenol was
added and the mixture incubated at 65°C for 60 min with vortexing every 10 min. The
mixture was then iced 5 min, centrifuged at 14,000 RPM for 5 min at 4°C, and the
supernatant removed to a new tube. An additional 500 µL phenol was added, the
solution vortexed, incubated 5 min on ice, and then pelleted at 3000 RPM for 5 min at
4°C. The supernatant was collected and 500 µL chloroform was added, the solution
vortexed, and pelleted at 3000 RPM for 5 min at 4°C. The supernatant was again
transferred, 50 µL 3M sodium acetate (pH 5.3) was added, mixed well, then 1 mL of icecold 100% ethanol (RNase-free) was added and the solution placed at -20°C overnight
to precipitate the RNA.
RNA purification and quantification— The precipitated RNA was pelleted at
14,000 RPM for 10 min at 4°C, washed with 1 mL 70% ethanol (DNase-free), and airdried for 30 min. The dry RNA was resuspended in 500 µL DEPC H2O and the
absorbance at 260 nm was measured using UV spectroscopy. The Turbo DNA-freeTM kit
was used to remove DNA from 30 µg of total RNA. After DNA removal the RNA
concentration was re-determined, and 0.3 µg was visualized on a 2% formaldehyde
agarose gel to ensure RNA quality.
cDNA synthesis— 1st strand synthesis was completed using 20 µg DNA-free
RNA for each replicate. A RNA:random primer ratio of 1:0.086 and a RNA:oligo (dT)
ratio of 1:0.0017 were used. The initial reaction containing RNA, random primers, and
oligo (dT) was incubated at 70°C for 10 min (denaturation) followed by 10 min at 25°C
(annealing) and held at 4°C. The synthesis reaction consisted of the annealed mixture,
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20 µL 5X 1st strand buffer, 10 µL 0.1M DTT, 5 µL dNTP + dUTP mix, 10 µL Superscript II
reverse transcriptase, and DEPC H2O to 105 µL. This reaction was placed in a thermal
cycler and the following program run: 25°C for 10 min, 37°C for 30 min, 42°C for 30 min,
and 70°C for 10 min to inactivate the enzyme. The template RNA was then digested by
adding 3 µL of RNase H and 3 µL of RNase cocktail and incubating at 37°C for 20 min.
The DNA was purified using the QIAquick PCR purification kit (Qiagen, Cat# 28104) and
eluted from the purification column in two 15 µL volumes. The cDNA was quantified
using UV spectroscopy measuring the absorbance at 260 nm, achieving a desired
concentration of greater than 0.1763 µg/uL cDNA.
Fragmentation and labeling— This step was completed using the Affymetrix
GeneChip WT Terminal labeling kit (Cat# 900670) according to the following protocol. In
a 0.2 mL PCR tube, 5.5 µg cDNA and water were added to a total volume of 31.2 µL. A
reaction mixture was prepared per reaction consisting of 10 µL DEPC H2O, 4.8 µL cDNA
fragmentation buffer, 1.0 µL UDG (10 U/µL), and 1.0 µL APE (1000 U/µL). The cDNA
was added to this reaction mixture and pulse spun, and run through the following
program in a thermal cycler: 37°C for 60 min, 93°C for 2 min, and 4°C for greater than 2
min. Labeling was done immediately following the fragmentation by adding 45 µL of the
fragmented cDNA, 12 µL 5X TdT buffer, 2 µL of TdT, and 1 µL of DNA labeling reagent
into a PCR tube. The labeling reaction was performed in a thermal cycler using the
following program: 37°C for 60 min, 70°C for 10 min, and 4°C for greater than 2 min.
Hybridization and statistical analysis— The labeled cDNA fragments were sent to
our local Affymetrix core facility, the Center for Integrated Biotechnology (CIB), Utah
State University, for hybridization to the GeneChip Yeast Genome 2.0 Array (Affymetrix
Cat# 900554) and subsequent data collection. The generated data was sent for
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statistical analysis to Dr. John Stevens in the Department of Mathematics and Statistics,
Utah State University.
RESULTS AND DISCUSSION
This study was directed at identifying any RNAs, including mRNAs, whose
degradation is affected by methyl transferase activity. Both wild type (Hmt1) and Hmt1null (Hmt1-/-) cells were readily grown and treated with the transcriptional inhibitor
thiolutin to stop production of new RNA. The RNA was given 45 minutes to degrade
before the cells were harvested. The cDNA, created from the extracted RNA, was then
fragmented and labeled for hybridization to a yeast whole-genome microarray.
Microarray analysis— Samples from two wild type and three Hmt1 -/- extractions
were compared using the yeast tiling array (S. cerevisiae Tiling 1.0R Array). The third
wild type sample was excluded due to quality concerns. The expression data gathered
was read into R using the Starr package. Each of the 2,697,594 probes were “mapped”
to the nearest gene, based on the starting position of the probe on the chromosome,
using the AffyTiling package in R. Each of the genes’ positions (beginning and end) and
chromosome

were

taken

from

the

yeast\genome.org

website

(http://www.yeastgenome.org/download-data/curation, accessed 5/21/12). There were
8,548 ‘genes’ (or genomic regions) represented among the probes after this mapping.
Due to the small sample size, Dr. Stevens chose a probe-level nested factorial
model to test for differential expression between Hmt1 -/- and WT conditions, following
RMA background correction and quantile normalization. This produced a p-value for
each of the 8,548 genomic regions summarized as a histogram (Figure 4-1). The
histogram plots frequency versus p-value, and a peak near zero is indicative of
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differential expression. Unfortunately, our crippled data yielded no peak near zero,
limiting the significance of our data.

Figure 4-1: Histogram of the probe-level nested factorial model. P-values for
8,548 genomic regions, which compares the relative levels of RNAs in wild type
(Hmt1) vs. Hmt1-null (Hmt1-/-) cells.

Some useful information may still be garnered from this experiment by analysis
of p-values of individual genes which are annotated to Gene Ontology or KEGG pathway
terms can be combined (using meta-analysis tools) to give p-values for each of those
terms. Applying this method can use subtle, non-significant, individual gene-level results
to make statements of significance regarding the Gene Ontology or KEGG pathway
terms.

The

appropriate

annotation

information

(http://www.yeastgenome.org/download-data/curation,

accessed

was

retrieved

5/21/12)

and

histograms created using this information indicate that there is strong evidence of some
differential activity of these terms (MF = molecular function, BP = biological process,
CC= cellular component, and KEGG) between the Hmt1 and WT conditions (Figure 4-2).
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Figure 4-2: Histograms of genes in different Gene Ontology (GO) of KEGG
pathway terms. P-values for genes in four different pathways categories: GO-MF
(molecular function), GO-BP (biological processes), GO-CC (cellular component),
and KEGG regions, which compares the relative levels of RNAs in wild type (Hmt1)
vs. Hmt1-null (Hmt1-/-) cells in combined groups.
In correlation to our broad pathways, yeast cDNA microarray analysis of RNA
immunoprecipitated with Myc-tagged Hmt1 from yeast cells found that Hmt1 was bound
to genes involved in a variety of functions, including general protein synthesis, metabolic
and catabolic pathways, creation and maintenance of cell wall, and glycolysis1.
Unfortunately, the loss of the third wild type sample which limited the significance of
individual RNAs put any direct gene comparisons on hold until an additional analysis of
extracted wild type RNA can be completed.
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CHAPTER 5
SUMMARY AND FUTURE WORK
REVIEW AND FUTRURE WORK
Proteins are a type of machinery cells employ for proper function and survival.
Creating new proteins is energetically expensive, and cells have evolved methods to
expand existing protein function to avoid some of these costs through the use of posttranslational modifications (PTMs). Protein arginine methylation, catalyzed by protein
arginine methyltransferases (PRMTs), is involved in a variety of biological processes, in
cellular pathways, and human diseases (reviewed in the introduction). To further our
understanding of how PRMTs function we have investigated the effects of
oxidation/reduction on the recombinant PRMT1 enzyme (Chapter 2), laid a foundation
for future work determining the specific chemical interactions between PRMTs and
substrates (Chapter 3), and set the stage for discovery of additional roles of arginine
methylation in RNA processing and surveillance (Chapter 4). A short summary of each
of these projects, as well as a future direction for them, is provided below.
Redox Chemistry and PRMT1
Our lab first discovered an increase in enzymatic activity upon the addition of the
reductant DTT after attempts to determine the binding rate constant of AdoMet for
PRMT1 were unsuccessful unless performed in the presence of DTT. Since then,
assays performed in the absence and presence of DTT showed activity increases
ranging from 1.5- to 75-fold (some data not shown) using a variety of PRMT1 constructs.
In the absence of a reductant, PRMT1 formed a very large unordered oligomeric mass
greater than 660 kDa. In the presence of DTT, the very large oligomeric state
transitioned to an oligomeric state less than 660 kDa. In order to understand how the
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PRMT1 enzyme was being reduced, I first mutated two likely cysteine residues to
serines, purified the constructs, and assessed their activity. These mutants exhibited
wild type characteristics, which indicated that these residues were not responsible. To
quickly identify if any cysteine was responsible, a complete cysteine to serine PRMT1
mutant was created. Methylation assays showed that the cysteine-less mutant no longer
exhibited either effect of DTT.
Having identified that a cysteine residue is responsible for the observed redox
chemistry, we wondered what was being changed mechanistically to slow the rate of
catalysis (kcat). A previously established procedure, which measured intrinsic
fluorescence quenching, was used to determine the Kd of AdoMet binding in the absence
and presence of DTT. The Kd of AdoMet for PRMT1 was mildly enhanced (1.7-fold) upon
the addition of DTT. However, this measurement was taken under equilibrium conditions
and multiple rate changes could be masked in the overall Kd. We again took advantage
of a previously established procedure, which used stopped-flow kinetics, and measured
the association constant of AdoMet for PRMT1. We discovered that AdoMet exhibits an
average association rate (k1) 21-fold higher in the presence of DTT. Interestingly, the
rate of AdoMet binding in the absence of DTT (approx. 5.5s-1), while much slower than in
the presence of DTT, is still more than 200-fold greater than the reported rate of the
methyl transfer step (0.022s-1)1 in the presence of DTT. While this change in AdoMet
binding does not completely explain the effects of DTT on our steady state kinetic data
(kcat), there are many parameters in the mechanism of PRMT1 that may be affected by
PRMT’s reduction, and therefore contribute to the steady state rate loss that have yet to
be examined. Determination of the transient kinetics of PRMT1 in the absence and
presence of DTT may shed additional light on which mechanistic steps are affected by
PRMT1 reduction.
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The data presented in Chapter 2 have shown that the enzymatic activity of
PRMT1 increases and the range of oligomeric states decreases upon reduction of the
enzyme. These data seemingly conflict with a previous study by Feng et al.1 who
showed that as the enzyme concentration is gradually increased, enzymatic activity and
oligomeric state increase to a plateau around 0.5 µM enzyme concentration. Merging our
study with theirs, we propose a hypothesis in which there is an extremely dynamic
equilibrium of oligomeric states which is regulated by both enzyme concentration and
oxidized/reduced enzyme states (Figure 5-1). On one side of the equilibrium, in a
reduced environment at low concentrations, Feng et al.1 has shown predominantly
monomers and dimers. On the opposite side of equilibrium, in an oxidized environment
at high concentrations, we have shown predominantly very large molecular weight
oligomers (>660kDa). We propose that increasing the concentration above 0.5 µM and
maintaining a reduced enzyme generates an equilibrium oligomeric state, a mixture of

Low Concentration
Reduced
Low Activity

Higher Concentration
Reduced
Maximal Activity

Higher Concentration
Oxidized
Low Activity

Small Oligomers
(Less than 200 kDa)

Equilibrium Oligomers
(200-600 kDa)

Massive Oligomers
(Greater than 600 kDa)

Figure 5-1: Pictorial representation of our PRMT1 equilibrium hypothesis.
Equilibrium of PRMT1 oligomerization shown by Feng et al. (left), data presented in
this thesis (right), and the hypothesized oligomeric equilibrium which exhibits
maximal enzymatic activity (middle).
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oligomers ranging in size from 42 to 600 kDa, which exhibit maximal enzymatic activity.
Coincidently, it is widely known that the cytosol is a reducing environment, and
unpublished data from our lab estimates the cellular concentration of PRMT1 to be
between 0.5 and 1.0 µM.
It is therefore essential that we discover any oxidation and reduction of PRMT1
occurring in vivo, which may consequently regulate arginine methylation. To identify if
PRMT1 is oxidized in vivo, we propose to measure the differences in the amount of free
thiols on PRMT1 in wild type and oxidatively stressed cells. Briefly, mammalian cells
treated to mimic oxidative stress can be lysed in the presence of a thiol capping agent,
such as iodoacetamide, which irreversibly reacts with all free protein thiols. This capping
agent does not react with oxidized thiols such as cysteines which are reversibly oxidized
to disulfides and sulfenic acids, or irreversibly oxidized to sulfinic and sulfonic acids. Any
reversible oxidation states can then be reduced which generates free thiols. These free
thiols can then be re-labeled using a different thiol-reactive reagent capable of producing
a measurable signal, such as fluorescence. Labeled PRMT1 can then be isolated by
immunoprecipitation (commercial antibodies available) and the amount of thiol oxidation
quantified.
While this does not directly prove that oxidation of PRMT1 in vivo is associated
with a decrease in enzymatic activity, we may extend this study using an activity probe
developed by Thompson et al.2. This fluorescent activity probe is a peptide-based
inhibitor

compound,

in

which

the

substrate

arginine

is

replaced

with

a

choloroacetamidine warhead, capable of irreversibly bonding with PRMT1. Previous
studies have shown that this activity probe can be used in vivo to assess PRMT1
activity2. Alternatively, the enzymatic activity of immunoprecipitated PRMT1 may be
tested using an established autoradiograph assay. Data showing lower enzymatic
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activity of PRMT1 generated in oxidatively stressed cells would indicate a novel
mechanism for regulating PRMT1 activity by oxidation and reduction of the enzyme.
Identifying Chemical Interactions between Hmt1 and Peptide Substrates
While much is known about the mechanism of PRMTs and the variety of
substrates they interact with, very little is understood about how PRMTs selectively bind
their substrates. Understanding the chemical details of how PRMTs target other proteins
for methylation sets the stage for therapeutic inhibitor development capable of
isoenzyme, substrate, and methylation state specificity. One of the many PRMT crystals
used to model PRMT structures (ratPRMT1) was co-crystallized with the R3 peptide
substrate and AdoMet3. Unfortunately, the R3 peptide backbone was modeled in three
orientations and the collected x-ray diffraction data was not sufficient to model the side
chain interactions of the peptide with PRMT1. After structural alignment of the rat
PRMT1 structure with the yeast Hmt1 structure, we modeled the three peptide
backbones onto Hmt1. Using this in silico model, we hypothesized that we could disrupt
peptide binding in two of the three putative grooves using site-directed mutagenesis.
Site-directed mutagenesis was used to create single-residue mutants with the
potential to block peptide binding. Initial methyltransferase assays with the R3 peptide
and three carefully designed asymmetric peptides did not clearly identify any mutants
capable of forming a homogenous complex; however there is a large discrepancy in the
activity of wild type Hmt1 in multiple preparations which hinders our ability to compare
mutant activities to that of wild type. In addition, the lack of consistent wild type activity
questions the validity of each of the mutant’s true activities. To continue this project we
much first eliminate the inconsistencies in wild type Hmt1 activity. A recent study showed
that phosphorylation of serine 9 (or a S9E mutation) was required for oligomerization
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and enzymatic activity in vivo4. Creating a S9E mutant will allow us to assay a
phosphorylated Hmt1 mimic. If this Hmt1 mutant, which better mimics in vivo realities,
yields consistent enzymatic activity, all mutants developed to sterically hinder peptide
binding will need to have this mutation introduced and be characterized again. After
achieving reliable enzymatic activity data which identifies a mutant(s) or multi-mutant(s)
capable of methylating only one peptide, the mutant:peptide combination(s) should be
put into crystal trials as a potentially homogenous Hmt1:peptide complex. This
homogenous protein crystal should be capable of generating x-ray diffraction data which
resolves specific chemical interactions between the side chains of the peptide and the
Hmt1 core. Identification of these interactions would lay a solid foundation for the in silico
development of PRMT inhibitors capable isoenzyme, substrate, and methylation state
selectivity.
Whole Genome Microarray Analysis of Total RNA Levels in S. cerevisiae
Proteins play an important role in RNA processing and surveillance in order to
form mature messenger RNAs (mRNAs)5–7. Hmt1 has been shown to be important in
these processes; however our understanding of what role arginine methylation plays is
limited. A previous study evaluated the levels of mRNAs in both wild type and Hmt1-null
yeast cell extracts and observed greater than 2-fold changes in 64 genes5. Hmt1 has
been shown to be inhibited by the proteins Air1 and Air2, members of the TRAMP
complex8. The TRAMP complex is responsible for many events in RNA processing and
is speculated to enable the nuclear exosome to efficiently degrade structured RNA9.
Since Hmt1 is regulated by a component of this complex, we sought to expand the
previous mRNA study by analyzing what mRNAs were affected by the loss of Hmt1
during RNA degradation. In addition, since the TRAMP complex interacts with tRNAs,
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snoRNAs, snRNAs, ncRNAs, rRNAs, some mRNAs, and cryptic unstable transcripts, we
sought to analyze all RNAs, not just mRNAs, present in our yeast cell extracts.
To do this analysis, we stopped production of new RNA during cell growth (using
the RNA polymerase inhibitor thiolutin) and allowed sufficient time for RNAs to undergo
degradation. The RNA was then extracted and assayed using a S. cerevisiae whole
genome microarray from Affymetrix. Unfortunately, one of our triplicate wild type
samples did not produce usable data and our statistical analysis was not sufficient to see
differences in specific genes. A broader perspective on RNA changes was obtained by
combining individual genes into pathway groups, identifying four pathways terms with
statistical changes in the wild type vs. Hmt1-null cells. These pathways include
molecular function, biological processes, and cellular components. In order for individual
gene analysis to become statistically significant additional data sets will need to be
gathered, which is cost-prohibitive. Once an additional hybridization is performed the
data can be re-analyzed and individual genes which change significantly when
comparing the wild type vs Hmt1-null cells can be identified, which will provide a
framework for further study of these individual genes.
SUMMARY
This thesis focused on understanding the effects of oxidation and reduction on
the enzymatic activity, oligomeric state, and mechanism of PRMT1. This project
currently has the most potential impact in the PRMT field because of its strong
implications, currently unmentioned in the literature, that PRMT activity may be regulated
by oxidative stress in vivo. In addition, this thesis describes the foundation for two
additional avenues of investigation into little understood areas in the PRMT field. The
first of these areas seeks to understand how PRMTs target substrates by identifying
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enzyme:substrate interactions at the atomic level. The second area investigates the
changes in total RNA levels influenced by the presence of Hmt1 in order to understand
what role arginine methylation plays in RNA processing and surveillance. Together,
these studies provide a foundation for future research which addresses the exciting
potential for oxidative regulation, the intricacies of substrate selectivity, and the role(s) of
arginine methylation in transcriptional regulation.
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